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TRICHURIS MURIS WHEY ACIDIC PROTEIN INDUCES TYPE 2 PROTECTIVE 
IMMUNITY AGAINST WHIPWORM 
 
Neima Briggs, B.S., D.T.M. 
 
Advisory Professors: Jagannadha Sastry, Ph.D. and Peter Hotez, M.D., Ph.D. 
 
Human whipworm (Trichuris trichiura) infects approximately 1 in 15 people worldwide, 
representing the leading infectious cause of colitis and subsequent, inflammatory bowel disease 
(IBD). Current control measures focused on mass deworming have had limited success due to 
low drug efficacies. Vaccination would be an ideal, cost-effective strategy to induce protective 
immunity, leading to control of infection and transmission. Here we report the identification of 
whey acidic protein, a whipworm secretory protein, as a strong immunogen for inducing 
protective efficacy in a surrogate mouse T. muris infection model. The near full-length 
recombinant WAP protein (rTm-WAP49), as well as a single, highly conserved repeat within WAP 
(fragment 8) expressed as an Na-GST-1 fusion protein (rTm-WAP-F8+Na-GST-1), generate a 
strong T helper type 2 (TH2) immune response when delivered as subcutaneous immunization 
formulated with Montanide ISA 720. Oral challenge with T. muris infective eggs following 
vaccination led to a significant reduction in worm burden of 48% by rTm-WAP49 and 33% by 
rTm-WAP-F8+Na-GST-1. The cellular immune correlates of protection included significant 
antigen-specific production of TH2 cytokines IL-4, IL-9, and IL-13 by cells isolated from the 
vaccine-draining inguinal lymph nodes, parasite-draining mesenteric lymph nodes, and spleen in 
mice vaccinated with either rTm-WAP49 or rTm-WAP-F8+Na-GST-1. The humoral immune 
correlates included a high antigen-specific ratio of IgG1 to IgG2a, without eliciting an IgE-
mediated allergic response. Immunofluorescent staining of adult T. muris with WAP antisera 
identified the worm’s pathogenic stichosome organ as the site of secretion of native Tm-WAP 
protein into the colonic mucosa. While both rTm-WAP49 or rTm-WAP-F8+Na-GST-1 have high 
 ix 
 
purity and stability properties by analytical analysis, rTm-WAP49 has a more complex biophysical 
profile, with oligomerization to dimers and trimers through intermolecular disulfide bond 
formation. Recognition of rTm-WAP49 by endemic patient serum samples suggests that 
conserved epitopes may exist between T. muris and T. trichiura (or possibly non-Trichuris 
nematodes) derived WAPs. To our knowledge, this is the first study identifying a promising 
immunogen for further investigation of its vaccine potential against T. muris and eventually 
against T. trichiura.   
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1.1 Soil Transmitted Helminths: the “Unholy Trinity” 
The three major soil-transmitted helminths (STHs) include, whipworms (Trichuris 
trichiura), hookworms (Necator americanus and Ancylostoma duodenale), and roundworms 
(Ascaris lumbricoides). These parasitic worm infections plague the world’s most impoverished 
billion people (3). The STHs fall into the broader grouping of neglected tropical diseases (NTDs), 
comprised of 20 diseases classified together by the World Health Organization (WHO) due to 
their longstanding public health disregard, despite affecting one-sixth of the global population (4). 
The STHs are the most prevalent infections among the NTDs and malaria (Figure 1) (5). 
According to the Global Burden of Disease Study of 2016, approximately 435 million people are 
infected with the whipworm, 800 million people are infected with the roundworm, and  450 million 
are infected with hookworms, the later mostly include Necator americanus infections (6).   
  
 
Figure 1. Global prevalence of neglected tropical diseases and malaria with age in 2016. 
This figure was generated with data from the Institute for Health Metrics and Evaluation at the 
University of Washington (5). 
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Recent estimates indicate that STH infections are responsible for 5.19 million disability 
adjusted life years (DALYs), which leads all NTDs (7). These intestinal parasites cause chronic, 
debilitating disease including iron deficiency anemia, asthma, vitamin deficiency, abdominal pain, 
colitis, and dysentery, leading to growth failure and impaired cognitive development (8). The STH 
infections perpetuate poverty within endemic communities due to economic suppression from 
decreased education accruement, loss of workforce, and cost of treatment (4, 9, 10). The NTDs, 
including STHs, are considered ancient diseases, with references in numerous ancient texts, 
including the Talmud, Bible, and the writings of Hippocrates (11). The STH eggs have even been 
identified in the mummified remains of human stool (3). It is theorized that over these millennia 
of host-parasite interactions, helminths evolved complex immune evasion capabilities and subtle 
clinical presentations to subvert detection and expulsion in humans (2). 
Our research group within the Texas Children’s Hospital Center for Vaccine Development 
has a long-standing interest in the NTDs, with a focus on vaccine development. A vaccine can 
serve as a low-cost and long-term solution to curb these poverty-promoting diseases. This 
dissertation will focus on one STH, Trichuris trichiura, with an emphasis on the identification and 
characterization of antigens along with investigating their immune-mediated mechanisms of 
protection in a murine model.  
 
1.2 Life Cycle and Pathogenesis  
Trichuris trichiura, known as the common whipworm of humans and nonhuman primates, 
is a parasite of the superfamily Trichinelloidea (1). Trichuris species are common parasites of the 
mammalian kingdom, but are relatively host-specific (12). For purposes of vaccine development, 
there is no established laboratory animal model for T. trichiura because of its specificity restricted 
to humans and some non-human primates (12, 13). Fortunately, the closely related Trichuris 
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muris parasite, specific to mice, has emerged as a useful surrogate model to screen for antigen 
immunogenicity and efficacy (14).  
In both cases of T. trichiura and T. muris, infection occurs through direct ingestion of 
embryonated eggs from contaminated food, soil, water, or via soiled hands (15). Ingested 
whipworm eggs hatch into larvae in the terminal ileum and caecum due to interactions with the 
host microbiome (16). At the cecum, the helminth embeds it’s anterior portion within the colonic 
epithelium and matures into adult worms in 1 to 3 months, in case of T. trichiura (17) or in 35 to 
42 days, in case of T. muris (14). In humans, T. trichiura can grow to approximately 3-5 cm in 
length, with the females slightly larger than the males and both living for 1-3 years, although there 
are reports of cases where they have survived substantially longer (17, 18).   
Trichuris spp. cannot complete its lifecycle within the host and must pass its 
unembryonated eggs from the posterior, intraluminal end of the parasite out of the animal with 
the passing bowel movement (18). An infected human can harbor dozens to thousands of adult 
whipworm (19). A single T. trichiura female can release 3,000 to 20,000 barrel-shaped ova a day, 
leading heavily-infected people to pass millions of eggs through their stool a day (18). The WHO 
defines the intensity (or burden) of infection based on the number of eggs per gram of feces, with 
light, moderate, and heavy infections quantified as 1-999, 1,000-9,999, and greater than 10,000 
eggs, respectively (18). The intensity of infection has been shown to correlate with disease 
severity (19). In the soil, the zygote egg development goes through an advanced cleavage stage, 
ultimately becoming embryonated, and infectious, after 10-14 days (19). The egg can remain 
viable for several years in soil and withstand high variations in temperature, allowing the parasite 
to subsist beyond tropics and into temperate climates (18, 19). 
Within the phylum Nematoda, both Trichuris whipworms and Trichinella, parasites 
causing trichinosis, belong to the order Trichocephalida (Figure 2) (20), which has as a hallmark, 
a unique parasite organ known as the stichosome (Figure 3) (14, 21). The stichosome is thought 
to enable burrowing of the anterior portion of the worm into the mucosal epithelium of the host to 
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provide the parasite an anchor preventing physical expulsion (21). Thus, the whipworm has both 
an intercellular existence at its anterior end, as well as an extracellular, intraluminal posterior 
end. The stichosome holds reservoirs of secretary granules containing macromolecules 
speculated to be necessary for host invasion into the colonic mucosa through pore-formation, 
enabling feeding, and modulation of host immune response (21–23).  Whipworms cultured in 
vitro release excretory and secretory products (ES) that are a rich source of antigens that this 
dissertation has used as a source for testing immunogenicity and efficacy towards future 
evaluation as potential vaccine candidates.  
 
 
 
 
 
 
 
 
Figure 2. Phylogenetic analysis of Trichuris spp. and the major human and zoonotic 
STHs. Evolutionary tree of T. trichiura and T. muris (green clade) within the phylum Nematoda.   
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1.3 Impact of Trichuriasis on Host Inflammation in the Intestines  
Associated with the public health impact of human soil-transmitted helminth infections, 
there is a profound level of global disability that arises from the pathologic sequelae of helminth 
infections translating into widespread mucosal immune and microbiome dysregulation and 
contributing to inflammatory diseases, such as asthma and inflammatory bowel disease (IBD) (2, 
24). For example, Ascaris larval invasion of the lung may induce asthma and other allergic 
pulmonary consequences, while the Trichuris stichosome invasion of the colonic mucosa 
ultimately results in chronic colitis, a suspected driver of IBD.  Although there are limited clinical 
Figure 3. Adult Trichuris muris stichosome. Light microscopy of anterior portion of adult 
female T. muris. The entire anterior, stichosome portion (~15 mm) embeds underneath and 
parallel to the colonic epithelium. The stichosome begins anterior to the vulva and extends until 
the mouth. Individual longitudinally-arranged stichocytes can be visualized throughout the 
stichosome.  The vulva on female whipworms mark the beginning of the posterior, reproductive 
portion (~8mm) of the worm that resides in the lumen of the intestines.  
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studies reporting IBD from rural helminth-endemic areas, underreporting of disease may be due 
to limited diagnostic resources (2). In an Ecuadorian cohort of over 2,400 children in Esmeraldas 
province, where 28.6% of children had at least one documented soil transmitted helminth 
infection, 25.9% of children had wheeze, 15.2% had skin test reactivity to an aeroallergen, and 
17.7% had an episode of eczema, suggesting a significant presence of allergic disease (2, 25). 
T. trichiura specifically attaches to the colon, where it can induce colitis, IBD, Trichuris dysentery 
syndrome, and rectal prolapse, especially in heavy infections (26, 27). The mechanisms 
responsible for these sequalae are likely a combination of direct tissue invasion by the adult 
parasite, together with a strong host inflammatory response.  Through such processes, long-
standing trichuriasis, similar to IBD, leads to growth suppression and cognitive impairments (28, 
29). These sequelae can sometimes resolve after treatment, resulting in catch-up growth (30). 
Use of T. muris as a model for of human IBD, has led to the identification of several key 
genes and immune correlates associated with susceptibility and severity (31, 32). Recent studies 
have shown that T. muris-infected colonic tissue histologically resembles established mouse 
models of IBD, with a defective epithelial barrier and a dominant TH1 immune infiltrate, leading 
to impaired intestinal mucosa homeostasis (32). Resistin-like molecule (RELMβ)—a protein 
secreted from goblet cells after local tissue damage triggers a proinflammatory cytokine milieu, 
with IFN-γ and tumor necrosis factor-alpha (TNF-α) cytokines driving the TH1 immune infiltration, 
leading to the chronic colonic pathology in both trichuriasis and IBD (33, 34). Mouse models of 
chronic trichuriasis result in massive crypt hyperplasia because of intra-epithelial lymphocytosis 
in the large intestines, hypothesized to be driven by a 43 kDa T. muris interferon-gamma (IFN-γ) 
homologue protein (35, 36). 
Interleukin 18 (IL-18), a key TH1 immune regulator of intestinal homeostasis, is 
overexpressed in the human large intestine during both Crohn’s disease and in T. muris-infected 
mice (37–39). Importantly, IL-18 production in T. muris-infected mice showed direct suppression 
of critical TH2 cytokines, IL-4 and IL-13, necessary for worm expulsion (37). Nowarski and 
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colleagues showed that overexpression of IL-18 led to significant mucosal barrier dysfunction, 
including epithelial goblet cell hyposecretion of protective mucins and other essential proteins for 
barrier integrity (40).  
The clinical, immunological, and histological homology, as well as genetic susceptibility, 
between Trichuris-induced colitis and both Crohn’s disease and ulcerative colitis warrants further 
investigation of Trichuris colitis as an environmental driver of IBD worldwide. For the purposes 
of this dissertation, we used several of the highlighted immune drivers of Trichuris colitis to 
evaluate the immune correlates of immunization-induced protection.    
 
1.4 Helminths and the “Hygiene Hypothesis” 
By some accounts, beginning in the late 20th century there was an increase in the 
reported cases of inflammatory and autoimmune diseases worldwide, such as asthma, 
inflammatory bowel disease (IBD), food allergies, and multiple sclerosis (MS) (41). This 
phenomenon has been linked to the evolution of a “westernized” lifestyle, declining family size, 
improved household amenities, higher personal cleanliness, and reduced cross infection within 
affluent communities (42). From this notion the “hygiene hypothesis” evolved, suggesting a 
reduction in microbial exposures, secondary to hygienic conditions, impeded the proper 
maturation of the immune system. The hygiene hypothesis has become accepted by many in the 
global scientific community and has evolved to associate multiple variables as either protective 
or contributory in the development of inflammatory diseases. Identified environmental factors that 
have been incorporated into the hygiene hypothesis include variations in microbial exposure, 
parasites, diet, medications, lifestyle behaviors, sanitation, occupations, and pollutant exposures 
(41, 43).  A branch of this hypothesis points at parasitic helminths, which according to some have 
been nearly eradicated from the westernized regions, as the key immune modulator necessary 
for proper immune development. 
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Despite the severe negative consequences of trichuriasis and helminth infections 
highlighted above, some studies present a counterview of generalized human helminth infections 
as potentially protective against the development of autoimmune and inflammatory diseases due 
to their significant immune modulatory properties within a host. Helminths can maintain host 
evasion for years through an array of mechanisms that down-regulate host innate and adaptive 
responses. These include immunomodulatory proteins containing host-related glycans and lipids 
that direct cytokine mimicry and interference, non-protein signature molecules that result in 
immunosuppressive host cytokine release, and direct interference of antigen presentation.  The 
presence of T regulatory cells (T reg) along with immune modulatory cytokines Interleukin-10 (IL-
10), transforming growth factor (TGF)-β, (44) and, at basal levels, Interleukin-18 (IL-18) (37) 
promote helminth survival while quelling the host inflammatory response.   
Ironically, despite the direct association of trichuriasis to IBD, there have been clinical 
trials with live helminths that aim to harness their anti-inflammatory properties as a treatment 
modality for patients with IBD. Initially, two open-label studies by Summers et al. showed that pig 
whipworm T. suis therapy for the treatment of IBD correlated to a remission rate of around 70%, 
helping ignite excitement for helminth therapy in human beings (45, 46). However, two blind, 
placebo-controlled Phase 2 clinical trials in the US with 250 patients, (TRUST-1, trial identifier 
NCT01576471) and in Europe with 240 patients, (FALK, trial identifier NCT01279577) using T. 
suis eggs for moderate-to-severe Crohn’s disease were terminated in 2013 due to a lack of 
efficacy, determined by both the disease activity index and remission rates (47, 48). Additionally, 
a Cochrane review, which is a meta-analysis of all relevant clinical trials and data on a health 
care intervention, found insufficient evidence of safety or efficacy of T. suis therapy to induce 
inflammatory bowel disease remission (49).  
To date the overwhelming scientific data point both to the harmful health effects of 
helminths, and the ability of helminth infections to impair economic development. Given the 
known risks of live helminth inoculations, research highlighting helminth immunomodulatory 
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properties should direct future research towards identifying specific helminth-derived molecules 
that could be developed into therapies. Further, it’s important not to diminish the role of helminths 
in inciting and exacerbating inflammatory diseases globally, including in wealthy countries such 
as the US. Therefore, prioritizing helminth elimination efforts globally through control tools such 
as anthelminthic drugs and vaccines remains paramount (2).  
 
1.5 Current Therapeutics: Limitations and Need for Innovation 
Global control of soil-transmitted nematode infections is based on annual (or sometimes 
twice-annual) mass drug administration with a single-dose of albendazole (400 mg), 
mebendazole (500 mg), tribendimidine (400 mg), pyrantel pamoate (10 mg/kg), or levamisole 
(2.5 mg/kg) for children between the ages of 1 and 14 who live in areas where the prevalence of 
these infections exceed 20% (50). The World Health Organization (WHO) has identified millions 
of children in every region of the world in need of treatment, although the call for treatment is 
substantially higher in the regions of Africa and South-East Asia due to increased prevalence 
(Table 1). The WHO estimates that in 2016, 69.5% of the world’s children who require mass 
treatment for STH, actually received their medication (51). The major goal of global deworming 
is morbidity reduction, especially to promote childhood growth and cognition, although 
increasingly there is interest in determining whether deworming itself might eventually lead to 
elimination of soil-transmitted helminthiases (52). Currently, pregnant women do not consistently 
receive anthelminthic treatments, due to unknown teratogenicity, leading to malnutrition and risks 
of fetal complications (53).   
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Aside from the low treatment coverage for children, a situation being remedied through 
expanded donations of albendazole and mebendazole and new global policies including a recent 
World Health Assembly resolution (54), there are concerns that pediatric mass drug 
administration alone may not be sufficient for global control of soil-transmitted nematode 
infections, and certainly not global elimination (55).   
The major reasons for why annual deworming may not be successful as an isolated 
intervention are: 
• High rates of post-treatment reinfection, especially in areas of intense transmission, which 
might require a higher frequency of deworming, in some cases every four months or more 
frequently (56). 
WHO Region 
 
Number of children 
requiring albendazole or 
mebendazole 
 
Percentage of worldwide 
population requiring 
treatment 
African 
(AFRO) 
296.5 million 33.8% 
Americas 
(PAHO) 
48.0 million 5.4% 
South-East Asia 
(SEARO) 
371.0 million 42.4% 
Europe 4.3 million 0.5% 
Eastern Mediterranean 
(EMRO) 
80.5 million 9.2% 
Western Pacific 
(WPRO) 
73.3 million 8.4% 
Globally 874.5 million 100% 
Table 1. Geographic distribution of children who require regular deworming.  This 
figure was adapted, with permission, from reference 1. 
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• A systematic review of the 5 available drugs (albendazole [400 mg], mebendazole [500 
mg], tribendimidine [400 mg], pyrantel pamoate [10 mg/kg], or levamisole [2.5 mg/kg]) 
against STHs revealed that none of these anthelminthics at the current single-dose 
regimen provided a satisfactory cure rate against trichuriasis (55, 57, 58). On the other 
hand, a single dose of albendazole, mebendazole, or pyrantel pamoate provided greater 
than 88% cure rates against A. lumbricoides (57). Similarly, a single dose of albendazole 
or tribendimidine provided 72% and 77.8% cure rate against hookworm, respectively (57, 
59). Thus, these anthelminthics are poorly effective against trichuriasis with cure rates for 
the recommended single dose regimens at, 28% for albendazole, 36% for mebendazole, 
23.1% for tribendimidine,  28.1% for pyrantel pamoate, and 8.6% for levamisole (57). 
Therefore, preventive chemotherapy has the least impact on human whipworm infection 
relative to other STHs. Yet another problem for trichuriasis are high rates of post 
treatment reinfection, especially without clean water and sanitation (60). As a 
consequence, the global prevalence of trichuriasis has decreased by just 16.7% between 
2005-2015 (61). In that same time period, hookworm disease had a similar decrease by 
just 14.3%, whereas ascariasis decreased by 36.5% (61). 
• The potential for drug resistance, which has already emerged in veterinary medicine for 
horses and cattle mass treated with benzimidazoles and macrocyclic lactones (57).    
• Failure to fully consider the transmission dynamics of soil-transmitted nematode 
infections, which affects both adult and pediatric populations and would require targeting 
of both populations for a truly effective elimination strategy (55). 
• Failure to co-implement aggressive programs of sanitation and access to clean water in 
order to complement deworming (62).  
A recent Cochrane analysis has questioned the benefits of mass treatments and deworming 
based on lack of consistent evidence for its beneficial impact on nutrition, anemia, and school 
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attendance or performance (63).  It is likely that some of the factors outlined above, i.e., rapid re-
infection and lack of drug efficacies, have a role in the Cochrane findings. However, the Cochrane 
analysis also did not differentiate between the effects of individual nematode species or their 
differential drug susceptibilities (54).  The Cochrane analysis partly blurs these findings by 
treating all soil-transmitted nematode infections and their treatments as equivalent (54).  
Nevertheless, there is an urgent need to improve effectiveness and efficiencies of global 
deworming to achieve key milestones and Millennium Development Goals.  Approaches to 
improve global deworming were recently suggested (55).  They include adding ivermectin, 
mebendazole, or oxantel pamoate to albendazole in areas where high levels of trichuriasis 
transmission occurs (55, 64, 65).   
To summarize, human trichuriasis represents one of the world’s leading causes of IBD, 
especially among children living in poverty.  The current approach towards global helminth 
control, namely regular deworming, has the least effect for human trichuriasis compared to other 
soil-transmitted helminth infections. 
A cost-effective practical approach to the global control and elimination of soil-
transmitted nematode infections is the development (and distribution) of anthelminthic 
vaccines that can be used in conjunction with chemotherapy.   
 
1.6 Status of Trichuris Antigen Discovery  
Whipworm has not been studied as extensively as hookworm or roundworm with respect to 
the cloning, expression, and evaluation of recombinant antigens for immunogenicity.  Hence the 
field is at an infancy stage for a vaccine development pipeline. The concept of a human vaccine 
targeting trichuriasis was first proposed by Prof. Derek Wakelin and his colleagues in the 1990s 
(66). Since then, most of the successes with T. muris infection in mice as the model have been 
associated with either the parenteral injection of adult-stage worm antigens, especially those 
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containing stichosome-derived proteins for determining efficacy, or their administration via 
mucosal routes (summarized in Table 2). 
• Worm extracts.  Homogenized adult T. muris antigens, either emulsified in complete 
Freund’s adjuvant (CFA) for subcutaneous immunization, or combined with cholera toxin 
for oral administration have been administered to several different mouse strains (66). 
The mucosal IgA response was enhanced significantly by oral vaccination to induce 
protection in BALB/c and C57BL/10 mice, but not in B10.BR mice for unknown reasons 
(66). In contrast, subcutaneous administration provided enhanced protective immunity in 
all three mouse strains (66).  
• ES Antigens.  Stichosome-related adult-stage Trichuris spp. excretory and secretory (ES) 
products have been identified as potential sources of protective antigens (67), although 
some stichosome proteins remain stored in the organ and are not actually secreted (68).  
Near-sterile immunity has been observed following immunization with adult ES products 
in multiple susceptible and resistant strains, in particular when co-formulated with 
complete Freund’s adjuvant (CFA) or incomplete Freund’s adjuvant (IFA) (66, 69–72). 
The protection elicited in susceptible AKR mice included reductions in parasite egg 
shedding and was associated with a TH2 peripheral lymph node responses to in vitro ES 
stimulation, namely IL-4 and IL-13 secretion into the cellular supernatant (69). Three 
pore-forming proteins derived from the ES were identified and these include: TM43 from 
T. muris, (73), and TT52 (23) and TT95 (21) from T. trichiura.  However, evaluation of 
immunogenicity or efficacy of these proteins has not been reported to our knowledge.  
• Trichinella antigens. Murine studies have identified cross-reactivity and cross-immunity 
between Trichuris and its phylogenetically related nematode genus, Trichinella,  proteins 
(74). Using ELISA, immunoprecipitation and immunoblotting, it was demonstrated that T. 
trichiura-infected mice had cross-reactive antibodies to T. spiralis (74). Shared stichocyte 
antigens have also been noted (75).  Among the defined candidate antigens identified 
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from T. spiralis that provide partial protection are an aminopeptidase (76), serine 
proteases  (77–79), parasite-derived cytokines (80), paramyosin (81), heat shock protein 
(79) and secreted antigens of 87 kDa, 53 kDa, and 43 kDa size with unknown function 
(81–83).   
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Antigen MW Functions Parasite 
stages 
Protective efficacy Reference 
Adjuvant 
Worm reduction 
(HR, LR) 
Trichuris muris 
T. muris 
adult 
worm 
extracts 
Various Unknown Adult 
CFA 
 
 
Cholera 
toxin 
HR(BALB/c)= 99.2%     
LR(C57BL/10)= 97.8%   
LR(B10.BR)= 41.4% 
 
HR(BALB/c)= 97.6% 
LR(C57BL/10)= 59.0%   
LR(B10.BR)= 17.8% 
(66) 
T. muris 
adult ES 
Various ES products Adult CFA LR(AKR) = 100% (69) 
Trichinella spirals 
TsAP 
54.7 
kDa 
Aminopeptidase Larva CFA/ IFA 
8.1% (adult worm) 
59% (muscle larva) 
(76) 
TspSP-
1.2 
35.5 
kDa 
Serine protease 
Larva invasion 
Adult, ES None 
34.92% (adult worm) 
52.24% (muscle larva) 
(79) 
rTs-
Adsp 
47 kDa Serine protease Adult Alum 46.5% (78) 
pVAX1-
Tsmif-
Tsmcd-
1 
59 kDa 
 
68 kDa 
Macrophage 
inhibitory factor & 
cysteine protease 
inhibitor 
All 
None 
 
Ubiquitin 
23.17% 
 
37.95% 
(80) 
rTs-Pmy 
 
102 kDa 
 
Binding to C8, C9 
(complement) 
Adult, 
Larvae 
ISA50 
21.8% (muscle larva) 
33.4% (induced by 
epitope 88-107aa) 
(81) 
Ts87 87 kDa Surface antigen Adult 
DNA carried by 
S. typhimurium 
29.8% (adult worm) 
34.2% (muscle larva) 
(82) 
Ts53 53 kDa 
Secreted 
glycoprotein 
Adult, 
larva, ES 
ND ND (83) 
Ts adult 
ES 
various ES products Adult ND 
98.4% (adult worm); 
82.9% (muscle larva) 
 
(84) 
Ts-
Hsp70 
70 kDa Heat shock protein Adult CFA 37% (79) 
ES: Excretory and secretory; CFA: Complete Freund’s adjuvant; HR: High responder; IFA: Incomplete Freund’s adjuvant; 
ISA50: Incomplete Seppic adjuvants 50; LR: Low responder; MW: Molecular weight; ND: Not done. 
 
Table 2. Summary of major Trichuris muris and Trichinella spirals antigens discovered.  
This figure was adapted, with permission, from reference 1. 
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As outlined above, there are no defined T. trichiura antigens identified for potential 
application towards vaccine development. Thus, there is still a need to identify T. trichiura 
antigens for evaluating immunogenicity and potential efficacy in suitable animal models. One 
approach to identify a vaccine antigen would be to select the major Trichinella antigens with the 
highest Trichuris spp. homology and test each in a T. muris animal model for protective immunity. 
Yet another approach would be to screen the protective Tm-ES or T. muris homogenate for 
immunodominant antigens. However, given the complexity of macromolecule composition is 
simpler in stichosome-derived ES compared to whole worm extracts, the former may represent 
a more attractive source for purposes of antigen discovery. Selected antigens can be cloned and 
expressed in bacteria (E. coli), yeast, or baculovirus vector platforms.  
Given the high degree of homology at the gene and protein levels for several 
antigenic sequences between T. trichiura and T. muris, we selected T. muris adult ES 
products for identifying proteins that could be cloned and expressed as recombinant 
protein immunogens. Since the adult T. muris ES induces near-sterile immunity against 
infective egg challenge (69), we generated and used the protective Tm-ES antisera to 
immunoscreen the T. muris adult stichosome cDNA library to identify targets for vaccine 
development.  
 
1.7 Immune Correlates of Protection Against Whipworm 
Immunological protection against whipworm will likely depend on combined humoral and 
cellular type 2 immune response directed against one or more molecules found in Trichuris ES, 
as highlighted in the human and animal model studies reviewed above. Although sera from 
immunized mice can confer protection via passive transfer, if the recipient mouse is 
immunosuppressed, sera alone is not protective (67). A cellular component is believed to be 
 19 
 
necessary to induce a resistant (type 2 immunity) vs susceptible (type 1 immunity) response 
against T. muris infection (14, 85).  
Of critical significance to mounting type 2 immunity are T helper type 2 (TH2) cytokines 
IL-4, IL-9, and IL-13 (14, 86). In this regard, it is well-established that the TH2 cytokine IL-4 is a 
critical mediator for enhancing antibody responses (87), whereas IL-13 is recognized for its role 
in promoting worm expulsion through goblet cell expansion, mucin production, and smooth 
muscle hypercontractility cc. Similarly, IL-9 mediates smooth muscle hypercontractility, as well 
as tissue mast cell maturation (88, 89). 
Both IL-4 and IL-13 bind to the IL-4Rα subunit to induce STAT6 signaling pathway and 
subsequent TH2 responses. Stat6-deficient mice splenocytes do not exhibit IL-4 secretion in 
response to in-vitro stimulation with UV-inactivated HSV-1 (90), have reduced systemic IL-4 and 
IL-5 levels to OVA antigen challenge (91), impaired ability of T lymphocytes to differentiate into 
TH2 cells (92), and no detectable IgE levels (91). Consequently, STAT6-/- mice develop both 
acute and chronic T. muris infections. The redundancy in IL-4 and IL-13 binding to IL-4Rα, in part 
explains why IL-4 deficient mice have reduced, but still partial resistance (89). Interestingly, 
whereas complete IL-4Rα ablation renders high susceptibility to helminth infection, the selective 
deficiency of IL-4Rα on T cells has no impact on worm burden (89). Rather, T cells may be critical 
for the production, rather than recognition, of IL-4, because T helper follicular cells induce IgG1 
class switching of B cells via IL-4 (87). Although IL-5 is key for the expulsion of other geohelminth 
infections, predominately through downstream activation and recruitment of gut eosinophils (93), 
ablation of IL-5, and lack of subsequent eosinophilia, had no effect on the development of 
protective immunity against T. muris (94). Similarly, ablation of mast cells through blocking of 
mast/stem cell growth factor receptor (SCFR), c-kit, led to no change in protective immunity  (94). 
This suggests that neither eosinophils nor mast cells play a key role in T. muris resistance. 
In general, TH2-driven protective immunity to T. muris infection is most closely associated 
with elevated parasite-specific serum IgG1 (14). Selby and Wakelin demonstrated that passive 
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transfer of serum or adoptive transfer of lymphoid cells conferred increased resistance to T. muris 
infection (67). This transfer of protective serum, however, only provided protection when 
administered at the time of infection, and even then, the degree of protection was variable (67). 
Wakelin later demonstrated that immunosuppressed mice receiving serum transfer showed no 
protection against challenge, suggesting that a cellular component in recipient mice is necessary 
to mediate expulsion (95). To determine whether associated humoral protection was through 
antibody-dependent cell-mediated cytotoxicity (ADCC) against T. muris, Betts and Else 
evaluated FcγR-deficient with a resistant background (BALB/K) and found no change in immunity 
or parasite expulsion. This suggests that ADCC may not play a major role in T. muris protection.  
 
1.8 Trichuriasis animal model 
Protective immunity to T. muris in mice is strongly influenced by host genetics (96). 
Resistant “high responder” inbred mouse strains, such as BALB/c, develop a TH2 cytokine 
response (IL-4, IL-9, and IL-13) to T. muris infection with a corresponding rise in parasite-specific 
IgG1 antibodies, leading to expulsion of worms and complete resistance to reinfection for at least 
60 days (1, 14, 97). Therefore, BALB/c mice are the primary model of choice for studying natural 
host resistance to T. muris. On the other hand, B10.BR, C57BL/6, and AKR mice serve as 
effective “low responder” efficacy models to evaluate candidate antigens, as they develop type 
1 immune response to T. muris challenge, leading to high-burden disease, yet develop a 
protective type 2 immune response, when vaccinated with protective antigens such as T. muris 
excretory and secretory products (Tm-ES) prior to challenge (66, 69, 75). Stat6-deficient mice, 
which have an almost exclusive TH1 immune response to infection, are commonly used as a T. 
muris maintenance model, as adult T. muris only survive for 2-3 days ex vivo. 
Previous studies in our lab tested multiple mouse strains and found the AKR mice from 
Jackson Labs are the most consistent model for acute, high dose infection (e.g. 300 embryonated 
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eggs). On the other hand, B10.BR and C57BL/6 are better models of chronic infection by a single 
low-dose or repeated low-doses, known as a trickle-infection, which may better simulate a natural 
exposure to Trichuris spp. eggs (14). Since female mice exhibit a stronger TH2 response and 
have increased resistance to T. muris (98), male AKR mice were used for these initial studies. 
Eventually, any identified candidate antigens would need to be evaluated for immunogenicity and 
efficacy in female mice.  
 
1.9 Vaccine Route and Adjuvant 
Both immune response and epitope recognition of immunogens can vary substantially 
with different routes of administration and co-formulated adjuvants.  Mucosal vaccination (i.e. 
oral, sublingual, or intranasal), is an obvious option for gut pathogens, such as STHs, as this 
route induces the most substantial gut immune response (99). Additionally, it has a major 
advantage over parenteral immunizations because of administration ease in low resource 
populations that STHs predominately afflict, as seen with the oral polio vaccine. Intranasal 
immunization with recombinant As14 protein coupled to cholera toxin B subunit induced a 64% 
reduction in worm burden against Ascaris suum in BALB/c mice (100). However, with T. spiralis 
equal efficacy (~55%) was observed when muscle larval homogenate formulated with cholera 
toxin was delivered by oral administration or the same homogenate formulated with CFA for 
subcutaneous delivery in the T. spiralis animal model (66). In the T. muris models, however, 
Robinson and colleagues showed that secretory IgA induced by oral immunization using T. muris 
adult homogenate with cholera toxin adjuvant only gives partial protection in certain mice strains 
(BALB/c & C57BL/10), whereas subcutaneous immunization using the same antigen with CFA, 
induces enhanced protection in all mouse strains (BALB/c, C57BL/10, B10.BR) tested and is 
closely associated with high systemic IgG1 titers (1, 66). In humans, oral vaccination against gut 
pathogens S. enterica serovar Typhi and Vibrio cholera led to variable induced immunity in 
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endemic populations due to underlying variability in the intestinal microbiota, which does not 
affect parenteral administration (101). 
As described earlier, protection against whipworm is closely associated with host TH2 
response. Thus, an adjuvant that direct hosts immunity in the direction of a TH2 response would 
be a logical choice for co-formulation. Although CFA is the primary adjuvant of selection, due to 
its high toxicity it would not translate for human use and is less used in animal testing (102). 
Montanide ISA 720 is a squalene-based water-in-oil emulsion used in over 50 clinical trials (103, 
104). Montanide ISA 720 has been well-demonstrated to induces a strong and long-term 
combined TH2/ TH1 response (102). Despite the dual TH2/TH1 response, Montanide ISA 720 
has been used in multiple efficacious helminth preclinical animal models, including in 
schistosomiasis and the closely related Trichinella spiralis (102–104). Additionally, aluminum-
based adjuvants, such as aluminum phosphate and aluminum hydroxide, are TH2-biased 
adjuvants widely used in humans and animals, including anthelminthic vaccines (105).  
 
1.10 Conceptual Framework and Hypothesis 
The long-term goal of our lab is to develop a vaccine against T. trichiura. We exploited 
the high degree of genetic sequence homology between T. trichiura and T. muris pathogens to 
identify immunogenic T. muris stichosome-derived proteins and investigated their ability to elicit 
protective immunity against intracellular parasite establishment.  
The central hypothesis of this dissertation is that Trichuris spp. stichosome secretory 
proteins will induce protective type 2 immunity in a murine model.  
To test this hypothesis, the following specific aims were carried out: 
1. Identification of T. muris stichosome-derived antigens and expression as recombinant 
proteins. 
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a) Identify highly abundant antigens in the T. muris stichosome cDNA expression library using 
sera from mice immunized with the Tm-ES. 
b) Express and purify identified antigens from the T. muris stichosome cDNA expression 
library as recombinant proteins. 
2. Evaluate the immunogenicity and efficacy of T. muris recombinant proteins in a murine 
model. 
a) Determine the protective efficacy of recombinant proteins corresponding to the two highly 
abundant T. muris stichosome antigens in the AKR mouse model. 
b) Determine the humoral immune responses induced by the T. muris stichosome antigens 
by ELISA analysis. 
c) Determine the T helper cell responses in spleen, draining lymph nodes, and mesenteric 
lymph nodes induced by the T. muris stichosome antigens using Luminex® analysis. 
3. Biophysical characterization and localization of a protective T. muris protein. 
a) Determine the location of expression of the native protein in adult T. muris. 
b) Assess the homogeneity and purity. 
c) Determine the secondary structure, thermostability, and post-translational modifications. 
4. In vitro evaluation of human immune recognition of protective T. muris protein. 
a) Determine the prevalence of T. trichiura in an endemic region of Honduras by qPCR. 
b) Evaluate serum IgG and IgE recognition of the protective T. muris protein in endemic 
participants by ELISA. 
c) Evaluate human T cell responses to the protective T. muris protein using Flow Cytometry 
and Luminex® analysis. 
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Chapter II 
Identification of T. muris stichosome-derived antigens and 
expression as recombinant proteins.  
 25 
 
2.1 Introduction 
 The current method to control trichuriasis by mass drug administration (MDA) employing 
albendazole or mebendazole does not reduce the overall prevalence or associated morbidity 
(106). Though vaccination is a long-term and cost-effective strategy to induce protective 
immunity, possibly leading to the control of infection and transmission, there are no commercially 
available anthelminthic vaccines (1). However, clinical trials are testing recombinant protein-
based vaccines against schistosomiasis (Sm-TSP-2 and Sm-14) (107) and hookworm (Na-GST-
1) (108). While DNA and mRNA vaccines hold promise as alternative strategies, they have yet 
to be successful in human trials (109, 110), Furthermore, recombinant protein vaccines against 
infectious diseases have a good safety record and low production costs (111).  
Currently, there are no approved vaccines for human whipworm (1). Potential sources of 
whipworms antigens include: the whole worm extract (63, 66), the worm’s excretory and 
secretory (ES) products (21, 23, 67–69, 73, 112), and defined candidate antigens corresponding 
to the closely related Trichinella spiralis (76–83) (Summarized in Chapter 1, Table 2). The 
helminths’ anterior-end organ, known as a stichosome, excretes products that facilitate invasion 
and maintenance of the parasite into the host’s gut epithelia (14, 22). The T. muris ES, thought 
to predominately originate from the stichosome, can be collected from the media of in-vitro 
cultured helminths. Near-sterile immunity against T. muris, both in chronic and acute models of 
infection, occurs via vaccination with adult-stage T. muris ES (69, 113). We chose to focus on 
identifying dominant T. muris antigens using protective Tm-ES antisera to immunoscreen the T. 
muris adult whole worm expressional cDNA library to select targets and express them as 
recombinant proteins for immunogenicity and efficacy testing in the AKR mouse model.   
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2.2 Materials and Methods 
 
Preparation of T. muris excretory and secretory (ES) products and generation of immune 
sera 
The T. muris ES products were obtained from the overnight culture of T. muris adult 
worms isolated from laboratory maintained STAT6/KO mice based on an established protocol 
(13, 69, 114). The protein concentration of Tm-ES was measured using a bicinchoninic acid 
(BCA) assay (Thermo Fisher Scientific, USA) and determined to be endotoxin free (<0.88 EU/ 
mg) by Charles River Endosafe®-PTS system (Charles River, USA). The concentrated T. muris 
ES products containing the stichosome-secreted proteins (100 µg/mouse) were formulated by 
emulsification with Montanide ISA 720 at 30:70 aqueous to oil based on volume, as described 
(103). The Tm-ES was administered to male AKR mice at 100 µg of antigen per dose in 100 µL, 
subcutaneously at the lateral tail base for a total of three immunizations at 2 week interval. Blood 
was collected from immunized mice 10 days after the last immunization by cardiac puncture. 
Serum was isolated from blood by centrifugation in serum-separating tube (Sarstedt, Germany) 
at 10,000 g for 5 minutes and stored at -80°C until assay. 
Immunoscreening of the T. muris adult cDNA library 
Mouse anti-ES sera were used to immunoscreen T. muris adult cDNA library to identify 
immunodominant antigens based on the methods described previously (115). Briefly, 5x104 
plaques of the cDNA library made from T. muris adult worm were plated on each LB agar plate. 
The expression of T. muris adult proteins was induced and transferred by covering each plate 
with a 10 mM IPTG soaked nitrocellulose membrane. The blotted membranes were incubated 
with 1:2,000 dilutions of mouse anti-ES sera and then reacted with HRP-conjugated goat anti-
mouse IgG (1:5000) (Invitrogen, USA). The putative positive clones were scored and selected 
for secondary screening with the same reagents until a single positive clone was obtained. 
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The DNA sequences of positive clones were determined by double strand DNA 
sequencing using vector flanking primers, T3 and T7 RNA polymerase promoters (5′-
TAATACGACTCACTATAGGG-3′ and 5′-ATTAACCCTCACTAAAGGGA-3′, respectively) 
(Thermo Fisher Scientific, USA) and sequenced by Lone Star Labs (USA). Nucleotide and 
deduced amino acid sequences were compared to existing sequences by BLAST searching in 
the GenBank (http://www.ncbi.nlm.nih.gov) and in the T. muris reference genome on WormBase 
ParaSite (http://parasite.wormbase.org/Trichuris_muris_prjeb126/). MUSCLE 3.8.31 was used 
for multiple sequence alignment, PhyML 3.1 for phylogeny, and TreeDyn 198.3 for phylogenetic 
tree rendering using one click analysis mode online at http://www.phylogeny.fr (116, 117). The 
two most highly abundant proteins identified from this screening are Tm-WAP and Tm-CAP-1. 
These two proteins were expressed as recombinant proteins and purified as described below. 
Expression and purification of Tm-WAPs and Tm-CAP-1  
DNA encoding for the rTm-WAP49, comprising 70% of the immunodominant Tm-WAP 
(amino acids 24-393), was amplified without signal peptide from the total T. muris adult cDNA 
using forward (5’-GCGAATTCGCTAAAATAGGTTCATGTCC-3’) and reverse (5’-
ATGCGGCCGCTCAATGATGATGATGATGATGCTCGGCAGTGCTGTCGTCTCGGT-3’) 
primers and subcloned into yeast expression vector pPICZαA (Invitrogen, USA) using the 
restriction enzyme sites of EcoRI and XbaI and confirmed by sequencing the vector flanking 
primers using α-factor and 3’AOX1, as previously described (118). The recombinant plasmids 
were linearized with SacI digestion and transformed into Pichia pastoris X33 by electroporation, 
according to the manufacturer’s recommendations (Invitrogen, USA). Transformed cells were 
plated on selective medium. Transformed colonies were then purified by streaking for isolated 
colonies on selective medium. The expression of recombinant Tm-WAP49 with 6His-tag at C-
terminus was induced in medium with methanol in 10 L fermentation for 96 hours. The expressed 
recombinant Tm-WAP49 was purified with immobilized metal affinity chromatography (IMAC), as 
previously described (119). 
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For cloning Tm-WAP-F8+Na-GST-1, DNA coding for the Tm-WAP repeat fragment 8, the 
most conserved (69-96%) of the 10 repeats of Tm-WAP, was synthesized by GenScript. Tm-
WAP-F8 was then fused with DNA coding for Na-GST-1 at N-terminus, a hookworm vaccine 
antigen with GST function that helps the solubilization of fusion protein (76, 108) and cloned into 
pET41a by using NdeI/NdeI/XhoI sites. The Tm-WAP-F8+Na-GST-1 was expressed as soluble 
recombinant fusion protein in E. coli BL21 under induction of 1 mM IPTG and purified with 
immobilized metal affinity chromatography. 
For cloning Tm-CAP-1, the DNA encoding for Tm-CAP-1 (Cysteine-rich secretory 
proteins, Antigen 5, and Pathogenesis-related 1 protein of Trichuris muris), without N-terminus 
signal peptide and C-terminus GPI anchor, was amplified from T. muris adult cDNA using forward 
(Tm-CAP-1-F2: GACATATGGCACCACTTACGGTCCCCAT) and reverse (Tm-CAP-1-R2: 
TCGCGGCCGCTCAATGATGATGATGATGATGTTCTCTTAGGAGAAGAACGT) primers and 
subcloned into E. coli expression vector pET41A (Novagen, USA) using NedI/NotI sites. The 
sequencing-confirmed correct recombinant plasmid was transformed into E. coli BL21 (DE3) and 
the recombinant Tm-CAP-1 protein (rTm-CAP-1) was expressed under 1mM IPTG induction at 
30 °C overnight. The rTm-CAP-1 was expressed as insoluble inclusion body and solubilized in 
8M urea. The rTm-CAP-1 with 8 his-tag at C-terminus was purified with IMAC. The purified urea-
denatured rTm-CAP-1 was refolded in the refolding buffer (250 mM Arginine, 150mM NaCl, 
50mM Tris, pH 8.0). 
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2.3 Results 
Immunoscreening for the identification of highly abundant T. muris excreted-secreted 
(ES) antigens  
Prior to the start of this dissertation, our lab found that parenteral immunization of Tm-ES  
formulated with Montanide ISA 720 adjuvant induced significant worm burden reduction (90%, 
p=0.0079) in AKR mice, similar to previous efficacy studies using Tm-ES with complete Freund’s 
adjuvant (CFA) (72) or incomplete Freund adjuvant (IFA) (69). Protective antisera from mice 
immunized with Tm-ES plus ISA 720 was used to screen the T. muris adult whole worm 
expressional cDNA library and identified a total of 102 positive clones. DNA sequencing revealed 
a whey acidic protein (Tm-WAP) as the most abundant of the candidates identified (63 clones). 
BLAST searching revealed that Tm-WAP shares 96.8% amino acid sequence identity with a 
gene product (TMUE_s0165000300) in the established T. muris genome on WormBase (120, 
121). The Tm-WAP protein consists of several repeats (3-10) of a 50 amino acid fragment that 
share 69-96% inter-fragment sequence identity and possess six conserved cysteines predicted 
to form multiple disulfide bonds (Figure 4A) (DiANNA 1.1) (122–124). The Tm-WAP gene shares 
high homology, defined at greater than 40% sequence alignment (125), with the T. trichiura 
putative porin proteins, TT95 (21) and TT52 (23), at 54% and 47% amino acid sequence identity, 
respectively (Figure 4B).  
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Figure 4. Amino acid sequences and phylogenetic analyses of WAP protein from T. 
muris. (A) The predicted 547 amino acid sequence of Tm-WAP. The predicted signal peptide 
is highlighted in red (SignalP 4.1). The Tm-WAP protein contains ten repeats of a whey acidic 
protein (WAP)-type disulfide core domain that were aligned using CLUSTAL W and prepared 
for display using BOXSHADE. Identical amino acids are shaded in black and similar amino 
acids in gray. This 50 amino acid domain contains 6 conserved cysteine residues. The 49 
kDa N-terminus was expressed in yeast as rTm-WAP49 (in red box). The repeat fragment #8 
was expressed in E. coli as Tm-WAP-F8 (in yellow box) using an Na-GST-1 expression tag. 
(B) Phylogenetic tree of Tm-WAP and its corresponding gene TMUE_s0165000300 to their 
respective homologues in different Trichuris species. 
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The second most abundant clone identified from the cDNA library screening was T. muris 
Cysteine-rich secretory proteins, Antigen 5, and Pathogenesis-related 1 (CAP-1) protein (35 
clones) (Figure 5A). The CAP-domain family (also known as SCP/TAPS) was previously 
identified based on its abundance in the secretome of whipworm and other soil-transmitted 
helminths (126, 127). BLAST searching revealed that Tm-CAP-1 shares 99.3% amino acid 
sequence identity with a gene product (TMUE_s0030008500) in the established T. muris genome 
on WormBase (120, 121). Tm-CAP-1 shares the highest homology with the T. suis SCP-like 
protein (accession number KHJ42268.1) and T. trichiura CAP-domain containing protein 
(accession number CDW52210.1), at 48% and 38% amino acid sequence identity, respectively 
(Figure 5B).  
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The near full-length Tm-WAP was expressed with a 6His-tag at C-terminus in Pichia 
pastoris X33 as a soluble protein and purified by IMAC. After multiple unsuccessful attempts at 
expressing the entire protein in E. coli, ultimately yeast was found to be an efficient expression 
platform.  The recombinant protein migrated at 49 kDa, therefore named rTm-WAP49. The most 
conserved repeat of Tm-WAP, fragment 8, was expressed with a Necator americanus glutathione 
s-transferase-1 (Na-GST-1)-tag at the N-terminus as a soluble recombinant fusion protein in E. 
coli BL21 under induction of 1 mM IPTG and purified with immobilized IMAC. In addition to 
improving the expression and solubility of the fusion protein, Na-GST-1 is a hookworm vaccine 
candidate (108), and selected for the potential as a future pan-anthelminthic vaccine candidate.  
The full-length recombinant Tm-CAP-1 protein was expressed in Escherichia coli (E. coli) BL21 
as an insoluble inclusion body and solubilized in 8M urea. The rTm-CAP-1 with an 8 his-tag at 
the C-terminus was purified with immobilized metal affinity chromatography (IMAC), as 
previously described (119). 
Figure 5. Amino acid sequences and phylogenetic analyses of CAP-1 protein from T. 
muris. (A) The predicted 361 amino acid sequence of Tm-CAP-1. The predicted signal 
peptide is highlighted in red (SignalP 4.1). (B) Phylogenetic tree and sequence identify of 
rTm-CAP-1 and corresponding gene TMUE (s0030008500), to their respective homologues 
in different Trichuris species.  
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2.5 Discussion 
With nearly a half-billion people afflicted, trichuriasis is one of the most prevalent 
infectious diseases in the world, and yet there are limited prophylactic and therapeutic options. 
A vaccine against human whipworm would provide a low-cost and long-term solution, yet the 
identification of candidates is lacking. Here we report the identification of two highly abundant 
secretory proteins, whey acidic protein (WAP) and Cysteine-rich secretory proteins, Antigen 5, 
and Pathogenesis-related 1 (CAP-1). Immunoscreening of the adult T. muris expressional cDNA 
library with protective Tm-ES antisera identified Tm-WAP, followed by Tm-CAP-1 as the most 
recognized proteins. The high degree of amino acid sequence identity for the CAP and WAP 
proteins between T. muris and T. trichiura also suggests that key immunological epitopes may 
be shared between the macromolecules. 
Validating our results identifying Tm-WAP as the dominant antigen from among the T. 
muris ES proteins, a recent report by Shears et al. (2018) identified that TMUE_s0165000300 
(Tm-WAP gene) amongst the most abundant proteins within T. muris ES (113). In these studies, 
Shears et al. divided T. muris ES into four sub-fractions using size exclusion chromatography, to 
search for protective immunogens on sub-fractions that induced protective immunity following 
immunization. Tm-WAP was recognized as a major component of two potent ES preparations, 
sub-fractions 3 and 4, which induced sterile (or near sterile) immunity against a subsequent low 
dose T. muris infection (113). The authors further described sub-fractions 3 and 4 as potent 
stimulants of IL-13 in infection-primed lymphocytes, likely contributing to their efficacy. Given that 
Tm-WAP is highly abundant within sub-groups 3 and 4, it is possible that it is one of the key 
protective components within these fractions. TMUE_s0030008500 (Tm-CAP-1 gene), however, 
was not reported among the Tm-ES fractions.   
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Chapter III 
Evaluate the immunogenicity and efficacy of T. muris 
recombinant proteins in a murine model   
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3.1 Introduction: 
 
The overarching goal of this research is to identify protective candidate antigens for the 
eventual development as a vaccine against trichuriasis. As described in Chapter 1, we identified 
two secretory proteins, Tm-WAP and Tm-CAP-1, by an immunoscreen of the T. muris cDNA 
expressional library using protective Tm-ES antisera. In this chapter we determine the induction 
of humoral and cellular immune responses by recombinant Tm-WAP and Tm-CAP-1 proteins 
and, subsequently, whether immunization provide efficacy against T. muris challenge.  
The closely related Trichuris muris parasite, specific to mice, is a well-established 
surrogate model for human T. trichiura disease pathophysiology and subsequent host immunity, 
used for evaluating the immunogenicity and efficacy of vaccine candidates (13, 14). In both mice 
and humans, ingested whipworm eggs hatch into larvae in the terminal ileum and caecum due 
to interactions with the host microbiome (16). There, the helminths’ stichosome is thought to 
secrete products (i.e. Tm-ES) that facilitate essential pore-formation in the host colonic mucosa 
and host immunomodulation (14, 22). Once embedded, the Trichuris worms become fixed in 
location, causing inflammation at the site of intracellular attachment and induce colitis-like 
pathology (14).. We and others have reported that immunization with T. muris ES product elicits 
protective immunity in murine models (69, 75, 128).  
Protective immunity in preclinical models correlates with T helper type 2 (TH2) responses, 
with production of cytokines IL-4, IL-9, and IL-13 along with IgG1 antibodies and high IgG1 to 
IgG2a ratios (14, 69, 75, 114, 129, 130). Conversely, susceptibility is characterized by a 
predominate TH1 response (IL-12 and Interferon [IFN]-γ) and IgG2a antibodies (14, 69, 129).  
Here we report that recombinant Tm-WAP (rTm-WAP49) induced significant protection 
against T. muris challenge, while recombinant Tm-CAP-1 was ineffective.  Protection against T. 
muris infection by rTm-WAP49 was associated with strong TH2 cellular and humoral immune 
responses.  
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3.2 Materials and Methods 
 
Ethics statement 
All animal procedures were conducted in accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The 
protocol was approved by Baylor College of Medicine Institutional Animal Care and Use 
Committee (IACUC - AN-6297) in compliance with the Animal Welfare Act, PHS Policy, and other 
Federal statutes and regulations relating to animals and experiments involving animals. 
Mice 
6-7-week-old male AKR mice were purchased from Jackson Labs (USA) and used at 5 
mice per group for immunogenicity analyses and 13-15 mice per group for efficacy studies. Mice 
for the challenge studies were infected by oral gavage of 300 embryonated eggs in 100 ul of 
diH2O. Worm burden and post-challenge immunological response were assessed at day 15 
post-infection. Blood collection at various time points was by tail bleeding and the terminal bleeds 
were collected by cardiac puncture at the time of sacrifice. The spleens, mesenteric lymph nodes, 
and inguinal lymph nodes were collected at the time of sacrifice, and immediately resuspended 
in complete RPMI media (RPMI 1640 with L-glutamine [VWR, USA], 10% heat inactivated FBS 
[VWR, Radnor, PA], and 1x pen/strep solution [Thermo Fisher Scientific, USA])  for 
immunological analysis. 
Immunization 
The protein concentration of each antigen (rTm-WAP49; rTm-WAP-F8+Na-GST-1; rTm-
CAP-1; Tm-ES) was measured using BCA (Thermo Fisher Scientific, USA) and each of the 
recombinant protein was also ascertained to be endotoxin free (<0.88 EU/ mg) by Charles River 
Endosafe®-PTS system (Charles River, USA). All immunogens were prepared in sterile, 
ultrapure grade phosphate-buffered saline (PBS) (VWR, USA) and emulsified with Montanide 
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ISA 720 at 30:70 aqueous to oil based on volume, as described (103). The Tm-ES as well as 
rTm-WAP49, rTm-WAP-F8+Na-GST-1, and rTm-CAP-1 were administered at 100 µg in100 µL 
per dose, subcutaneously at the lateral tail base.  
T. muris parasite challenge 
T. muris E (Edinburgh) isolate, kindly provided by Dr. Joe Urban from the USDA, were 
maintained in susceptible STAT6K/O mice. At day 42 post infection (p.i.), adult worms were 
gently extracted by forceps from the caecum of sacrificed mice. T. muris eggs collected from 
cultured T. muris adult worms were washed in sterile water and centrifuged at 500xg for 5 
minutes and supernatant debris was removed from pelleted eggs. Collected eggs were stored in 
distilled water in culture flasks (VWR, USA) and allowed to embryonate at room temperature in 
the dark for 8 weeks. 300 embryonated eggs were separated into 100 µL aliquots. Each aliquot 
was counted by light microscopy to verify 300 ± 10 embryonated eggs. 
Antibody analysis 
Sera were isolated from blood by centrifugation in serum-separating tube (Sarstedt, 
Germany) at 10,000 g for 5 minutes and stored at -80°C until assay. Samples were evaluated for 
antigen-specific immunoglobulins IgG (Lifespan Biosciences, USA), IgG1 (Lifespan Biosciences, 
USA), IgG2a (Lifespan Biosciences, USA), and IgE (SouthernBiotech, USA) by a modified 
indirect enzyme-linked immunosorbent assay (ELISA), as described previously (131). 
Concentrations of rTm-WAP49 (0.375 µg/mL), rTm-WAP-F8+Na-GST-1 (0.375 µg/mL), rTm-
CAP-1 (0.375 µg/mL), rNa-GST-1 (0.375 µg/mL), or Tm-ES (0.75 µg/mL) used for ELISA were 
selected based on pretested optimal signal/noise ratio. The absorbance was measured by dual 
wavelength analysis at test wavelength of 450 nm and the reference wavelength of 630 nm using 
a spectrophotometer (BioTek, USA). 
Cytokine analysis  
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Spleens, mesenteric lymph nodes (MLNs), and inguinal lymph nodes (ILNs) were 
obtained from mice two weeks after the third immunization (immunogenicity groups) or 15 days 
after challenge infection (efficacy groups). We identified the ILNs as the primary site of vaccine 
drainage when administered subcutaneously at the lateral tail base by tracking 5% Evan’s Blue 
ink drainage 30 minutes after administration, as described by Harrell et al. (132). Tissues were 
disassociated into a single-cell suspensions using a 100 μm cell strainer and resuspended in 
complete RMPI medium. After a 5-minute centrifugation (300 x g), splenocytes were 
resuspended in 2 mL of ACK lysis buffer (Thermo Fisher Scientific, USA) and incubated at room 
temperature for 5 minutes to remove red blood cells. After centrifugation cells were resuspended 
in complete RPMI media and incubated for 2 hours in a 37°C + 5% CO2 incubator before counting 
the number of live cells using a Cellometer Auto 2000 Cell Viability Counter (Nexelcom, USA). 
To have sufficient cells for multiple cytokine assays, MLNs and ILNs, were separately pooled into 
3 sets of 5 mice per tissue.  
Cells were seeded in a 96-well U-bottom culture plate (Corning, USA) at 1x106 cells per 
well in 250 μl medium and restimulated with either rTm-WAP49 (10 µg/mL), rTm-WAP-F8+Na-
GST-1 (10 µg/mL), rTm-CAP-1 (10 µg/mL), rNa-GST-1 (10 µg/mL), or Tm-ES (50 µg/mL) at 
37°C, 5% CO2 for 72 hours. An unstimulated, media only negative control and a positive control 
where cells were activated with a mixture of 20 ng/mL PMA and 1 μg/mL Ionomycin were included 
in all the assays. After 72 hours the cells were pelleted by centrifugation at 300 x g for 5 min and 
the supernatants were collected for measuring the amount of cytokine produced. Concentrations 
of different stimulants and duration of stimulation were selected based on optimal pretested 
antigen to negative control ratio. Initially supernatant samples were tested using a custom Bio-
Plex Pro Mouse Cytokine 10-plex kit (Bio-Rad, USA) for determining the levels of IL-4, IL-5, Il-6, 
IL-9, IL-10, IL-12(p70), IL-13, IL-17A, IFN-γ and TNF-α. To evaluate accessory 
cytokines/chemokines associated with protection, subsequent experiments used the expanded 
Bio-Plex Pro Mouse Cytokine 23-plex kit, which included the original 10 cytokines along with 
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Eotaxin, G-CSF, GM-CSF, IL-1α, IL-1β, IL-2, IL-3, IL-12 (p40), KC, MCP-1 (MCAF), MIP-1α, 
MIP-1β, and Rantes. To increase the sensitivity of the experiment, the kit was used in 
combination with DA-Bead plates (Curiox Biosystems, Singapore), as previously described 
(133). Samples were run on a Luminex® Magpix® multiplex reader according to manufacturer's 
recommendations (Luminex, USA) and analyzed using the Bio-Plex Manager 6.0 software (Bio-
Rad, USA). Sensitivity cutoff values for the detection of different cytokines were dependent on 
the included standards for each lot number of the Bio-Rad Bio-Plex kit. Cytokine values from 
supernatants of cells cultured with media only were deemed background and thus were 
subtracted from the values of antigen stimulated samples.  
Electrophoresis and immunoblotting of recombinant Tm-WAP proteins  
Samples were subjected to electrophoresis using a 4-20% gradient NuPAGE/MES gel (Thermo 
Fisher Scientific, USA) and either immediately stained with Coomaisse Blue for imaging analysis 
or transferred onto PVDF membrane (Thermo Fisher Scientific, USA). Subsequently, the PVDF 
membranes were blocked with 5% (w/v) skim milk powder in PBST (PBS +0.05% Tween-20), 
and then incubated with sera (1:3,000) from immunized mice (rTm-WAP49, rTm-WAP-F8+Na-
GST-1 or Tm-ES. HRP-conjugated goat anti-mouse IgG (Invitrogen, USA) was used as a 
secondary antibody, followed by ECL substrate (GE Healthcare, USA) to develop antibody bound 
bands. The nitrocellulose membranes of anti-rTm-WAP-F8+Na-GST-1 and anti-Tm-ES were cut 
just prior to ECL substrate reaction between lanes 4-5 and 3-4, respectively, to allow for different 
length of reaction. Both T. muris adult homogenate and Tm-ES were used at 10 µg for SDS-
PAGE and 2.0 µg for western blot analyses. The rTm-WAP49 protein was used at 2 µg for SDS-
PAGE and 200 ng for western blot. Both rTm-WAP-F8+Na-GST-1 and rNa-GST-1 were used at 
2 µg for SDS-PAGE and 100 ng for western blot. 
Data presentation and statistical analyses 
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Figures 6-16 were generated in GraphPad 7.04, with the exception of Figure 7 A-C, 
Figure 10 A-C, and Figure 14 B, D, and F, and Figure 15 B. To compare groups based on data 
from unknown normality of distribution and small sample size (n < 20 per group), we performed 
non-parametric analyses employing Kruskal-Wallis H test with Dunn’s Multiple Comparisons and 
Mann-Whitney U test using GraphPad Prism version 7.04 for Windows, GraphPad Software, La 
Jolla California USA (www.graphpad.com).  
Figure 7 A-C, Figure 10 A-C, and Figure 14 B, D, and F, data was loaded into R 
programming language environment version 3.4.3 using Rstudio version 1.1.423 
(http://www.rstudio.com/). Readxl package was used to import the data from the spreadsheet 
(https://CRAN.R-project.org/package=readxl). Tidyverse package (version 1.2.1) was used to 
transform the imported data for the analysis (https://CRAN.R-project.org/package=tidyverse).  
Mean value for each cytokine in a group was calculated by bootstrapping using smean.cl.boot 
function with the default setting of Hmisc package (version 4.1-1) (https://CRAN.R-
project.org/package=Hmisc). We used Wilcox test for comparing values of each cytokine 
between groups using coin package (version 1.2-2) and the effect size was calculated using Cliff 
delta using effsize package (134, 135). A plot of the calculated results was generated using 
ggplot2 package (version ggplot2 2.2.1) (136). 
For all graphs, statistical significance: *p<0.05, **p<0.01 ***p<0.001, ****p<0.0001. Effect 
size: d<0.2, d<0.5, d<0.8, and d>0.8, correspond to N (negligible), S (small), M (medium), and L 
(large), respectively. 
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3.3 Results 
 
Immunogenicity and protective efficacy of recombinant Tm-WAP and Tm-CAP-1 proteins  
As described in chapter II above Tm-CAP-1 protein expression in E. coli was successful, 
but expression of Tm-WAP necessitated changing the vector system from E. coli to yeast. 
Therefore, while the expression of Tm-WAP and the purification of the recombinant protein were 
in progress, we expressed the most conserved repeat of Tm-WAP, fragment 8, with a Necator 
americanus glutathione s-transferase-1 (Na-GST-1)-tag at the N-terminus and successfully 
produced a soluble recombinant fusion protein in E. coli. The resulting recombinant protein, rTm-
WAP-F8+Na-GST-1 was tested for immunogenicity along with recombinant Tm-CAP-1 protein 
in the AKR mouse model.  
Mice were immunized three times at two-week intervals with Tm-ES, rTm-WAP-F8+Na-
GST-1 or rTm-CAP-1 using the Montanide ISA 720 adjuvant (Figure 12A).  Montanide ISA 720 
is a squalene-based water-in-oil emulsion used in multiple efficacious helminth preclinical animal 
model studies, including the closely related Trichinella spiralis, with safety in humans (102–104). 
Control groups included mice injected with PBS or adjuvant alone. Two weeks after the final 
immunization, serum levels of antigen-specific IgG1 and IgG2a were determined by ELISA to 
calculate end-point titers. Mice immunized with Tm-ES, rTm-WAP-F8+Na-GST-1, or rTm-CAP-
1 exhibited significant levels of respective antigen-specific IgG1 as well as IgG2a titers relative 
to those in control groups of mice immunized with PBS or adjuvant ISA-720 (Figure 6A and 6B). 
However, antigen-specific IgG2a levels were significantly higher in mice immunized with rTm-
CAP-1 relative to those in mice immunized with Tm-ES (Figure 6C). Consequently, mice 
immunized with rTm-CAP-1 had a significantly lower IgG1:IgG2a ratio relative to those 
immunized with either Tm-ES or rTm-WAP-F8+Na-GST-1 (Figure 6D).  
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Figure 6. Humoral immune responses induced by immunization with rTm-WAP-F8+Na-
GST-1 and rTm-CAP-1 proteins in the AKR murine model. (A) Scheme for immunization 
and sample collection. Humoral immune response was measured by determining the end-
point serum titer for antigen-specific (B) IgG1 and (C) IgG2a by ELISA to calculate the (D) 
IgG1 to IgG2a ratio for the mice in each group. Mice in groups injected with PBS or Montanide 
ISA 720 adjuvant were used as negative controls. Statistical significance: *p<0.05, **p<0.01 
***p<0.001, ****p<0.0001. 
A 
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Next, an analysis of antigen-specific T cell response of mice immunized with the different 
antigens was conducted. Spleen cells were isolated and restimulated with the corresponding 
candidate proteins for 72 hours in vitro, with Tm-ES serving as a positive control. In comparison 
to the mice in the two negative control groups (PBS or adjuvant control) antigen-specific T cell 
responses in mice immunized with Tm-ES (Figure 7A), rTm-WAP-F8+Na-GST-1 (Figure 7B), 
and rTm-CAP-1 (Figure 7C) were significantly increased. While there was a significant difference 
in IFN-γ production between mice immunized with rTm-WAP-F8+Na-GST-1 compared to rTm-
CAP-1 when stimulated with cognate antigen (p=0.003) (Table 3), there was no difference in 
IFN-γ production between mice immunized with rTm-WAP-F8+Na-GST-1 compared to control 
mice immunized with ISA 720 adjuvant when stimulated with rTm-WAP-F8+Na-GST-1 (p>0.999) 
(Figure 7B). On the other hand, production of TH2 cytokines IL-4 and was significantly higher in 
mice immunized with either rTm-WAP-F8+Na-GST-1 (p=0.011) or Tm-ES (p=0.048) compared 
to those immunized with rTm-CAP-1 when stimulated with cognate antigen (Table 3).  
Cumulatively, there was a larger TH2 response in mice immunized rTm-WAP-F8+Na-GST-1 and 
Tm-ES compared to those immunized with rTm-CAP-1 (Figure 7) 
A 
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Figure 7. Cellular immune responses in terms of cytokine levels in the supernatants of 
splenocytes stimulated with media or cognate antigens. Splenocytes from mice in each 
group were stimulated with media or cognate antigen, (A) Tm-ES, (B) rTm-WAP-F8+Na-GST-
1, or (C) rTm-CAP-1 for 72 hours and the cytokines were detected using a 10-plex assay kit. 
Mice in groups injected with Montanide ISA 720 were used as negative controls. Cells 
receiving no stimulus (media only) were subtracted as background from stimulated cells from 
corresponding mice. Values from duplicate wells for each treatment/stimulation were 
averaged for individual cytokines for the 5 mice in each group to calculate statistical 
significance. Data are presented as means ± 95% confidence interval. Statistical significance: 
*p<0.05, **p<0.01 ***p<0.001, ****p<0.0001. Effect size: d<0.2, d<0.5, d<0.8, and d>0.8, 
correspond to N (negligible), S (small), M (medium), and L (large), respectively. (D) Levels of 
TH1 and TH2 cytokines produced in response to stimulation with cognate antigens are shown 
as stacked columns. 
  
 
Table 3. Analyses of TH1 and TH2 cytokine levels in the supernatants of cells 
stimulated with Tm-ES, rTm-WAP-F8+Na-GST-1, or rTm-CAP-1. Cytokine levels of ES 
(Tm-ES), WAP-F8  (rTm-WAP-F8+Na-GST-1), and CAP (rTm-CAP-1) were compared by 
Kruskal-Wallis H test with Dunn’s Multiple Comparisons. Data are presented as mean. 
Statistical significance: not significant (NS)>0.05, *p<0.05, **p<0.01 ***p<0.001, 
****p<0.0001. 
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To evaluate whether the pronounced TH2 immune responses induced in mice immunized 
with the different antigens were effective in controlling T. muris infection, mice immunized with 
rTm-WAP-F8+Na-GST-1, rTm-CAP-1, Tm-ES, or Montanide ISA 720 adjuvant alone were 
challenged orally with 300 embryonated T. muris eggs two weeks after the final immunization. 
The intestinal worm burden was assessed 15 days post-infection by direct microscopy (Figure 
8A). In agreement with data from our earlier reported studies and those of others (69, 113), mice 
immunization with the positive control Tm-ES exhibited a significant reduction (93%, p<0.0001) 
in mean worm burden compared to mice immunized with Montanide ISA 720 adjuvant alone 
(Figure 8B). Furthermore, immunization with rTm-WAP-F8+Na-GST-1 also induced significant 
protection (27% reduction in worm burden, p=0.0124), while mice immunized with rTm-CAP-1 
showed only 3% reduction in worm burden (p=0.845).  
 
 
 
A 
B 
Figure 8. Protective efficacy of rTm-WAP-F8+Na-GST-1 and rTm-CAP-1 proteins. (A) 
Immunization and challenge schedule. (B) Efficacy in terms of reduction in worm burden in 
the different groups of immunized mice was evaluated on day 15 post-infection by counting 
the numbers of worms in the intestines by microscopy. 
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In addition to strong humoral and cellular TH2 response generated by vaccination, a 
continued TH2 immune response is necessary during the “critical period” of worm expulsion (day 
0-21 p.i.) (69). To evaluate the humoral response post challenge, we measured the antigen-
specific IgG1 (Figure 9A) and IgG2a (Figure 9B) levels in the serum along with T cell responses 
in splenocytes after restimulation in vitro with the cognate antigens to the initial immunization. In 
mice protected by immunization with Tm-ES or rTm-WAP-F8+Na-GST-1, relative to adjuvant 
control mice, we observed a significant increase in TH2 immune responses, characterized by 
high IgG1:IgG2a ratios (Figure 9C). Antigen-specific IgG1:IgG2a ratios were significantly lower 
in mice immunized with non-protective rTm-CAP-1 compared to protective Tm-ES and rTm-
WAP-F8+Na-GST-1 
Figure 9. Post-challenge humoral immune response in mice immunized with rTm-WAP-
F8+Na-GST-1 and rTm-CAP-1 proteins. End-point serum titers for antigen-specific (A) IgG1 
and (B) IgG2a were determined by ELISA to calculate the (C) IgG1 to IgG2a ratio for the mice 
in each group. Mice in groups injected with Montanide ISA 720 were used as negative 
controls. Statistical significance: *p<0.05, **p<0.01 ***p<0.001, ****p<0.0001. 
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 Post-challenge cellular response was measured in the supernatant of splenocytes 
stimulated with cognate antigens Tm-ES (Figure 10A), rTm-WAP-F8-Na-GST-1 (Figure 10B) 
and rTm-CAP-1 (Figure 10C).  As with pre-challenge, mice immunized Tm-ES, rTm-WAP-F8-
Na-GST-1 or rTm-CAP-1 had no significant difference in production in TH1 cytokines IL-12 or 
IFN-γ in splenocytes stimulated with cognate antigen (Table 4). However, the levels of TH2 
cytokines IL-4, IL-5, and IL-13 were significantly higher for all three antigen groups compared to 
adjuvant alone (Figure 10A-C). Production of TH2 cytokine, IL-9, which is important for worm 
expulsion through enhancement of gut peristalsis and tissue mast cell maturation (88, 89), was 
only elevated in mice immunized with Tm-ES (p=0.007) and nearly so for rTm-WAP-F8-Na-GST-
1 (p=0.054), compared to mice immunized with rTm-CAP-1 (Table 4). Furthermore, mice 
immunized with rTm-CAP-1 had significantly lower levels of TH2 cytokines, namely IL-4 
(p<0.0001), IL-5 (p=0.006), and IL-13 (p<0.0001) when compared to those in mice immunized 
with rTm-WAP-F8+Na-GST-1 (Table 4). A similar result was seen between mice immunized with 
Tm-ES compared to rTm-CAP-1 (Table 4). The cumulative TH2 cytokine level between rTm-
WAP-F8+Na-GST-1 and Tm-ES was comparable (Figure 10D).  
 
A 
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Figure 10. Post-challenge cellular immune responses in terms of cytokine levels in the 
supernatants of splenocytes stimulated with media or cognate antigens. Splenocytes 
from mice in each group were stimulated with media or cognate antigen, (A) Tm-ES, (B) rTm-
WAP-F8+Na-GST-1, or (C) rTm-CAP-1 for 72 hours and the cytokines produced were 
detected using a 10-plex assay kit.  Values for the levels of cytokines from cells receiving no 
stimulus (media only) were subtracted as background from those in cells stimulated with the 
cognate protein in the corresponding mice. Values from duplicate wells for each 
treatment/stimulation were averaged for individual cytokines for the 13-15 mice in each group 
to calculate statistical significance. Mice in groups injected with Montanide ISA 720 were used 
as negative controls. Data are presented as means ± 95% confidence interval. Statistical 
significance: *p<0.05, **p<0.01 ***p<0.001, ****p<0.0001. Effect size: d<0.2, d<0.5, d<0.8, 
and d>0.8, correspond to N (negligible), S (small), M (medium), and L (large), respectively. 
(D) Levels of cytokines for each group are shown as stacked columns based on TH1 vs TH2 
classification for each cognate antigen. 
 
D 
Table 4. Analyses of post-challenge TH1 and TH2 cytokine levels in the supernatants 
of cells stimulated with Tm-ES, rTm-WAP-F8+Na-GST-1, or rTm-CAP-1. Cytokine levels 
of ES (Tm-ES), WAP-F8  (rTm-WAP-F8+Na-GST-1), and CAP (rTm-CAP-1) were compared 
by Kruskal-Wallis H test with Dunn’s Multiple Comparisons. Data are presented as mean. 
Statistical significance: not significant (NS)>0.05, *p<0.05, **p<0.01 ***p<0.001, 
****p<0.0001. 
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Recombinant WAP protein (rTm-WAP49) induces strong type 2 protective immunity 
After initial unsuccessful attempts to express Tm-WAP in E. coli, rTm-WAP49 comprising 
of nearly eight of the ten, 50 amino acid repeats that make-up the full-length Tm-WAP protein 
was expressed in Pichia pastoris X33. We evaluated the immunogenicity and protective efficacy 
of rTm-WAP49 in comparison to that of rTm-WAP-F8+Na-GST-1 following the immunization and 
challenge schedule  shown in Figure 8A. Since the WAP fragment 8 was expressed and used 
with the Na-GST-1 tag for the immunization and challenge studies described above, and because 
Na-GST-1 corresponds to a hookworm candidate vaccine antigen, we decided to verify the 
contribution of the Na-GST-1 tag within the rTm-WAP-F8+Na-GST-1 for the observed protective 
efficacy against T. muris. Therefore, the recombinant Na-GST-1 protein was included as an 
additional control immunogen. Montanide ISA 720 adjuvant alone and Tm-ES were used as 
negative and positive control reagents, respectively. Endpoint titers of antigen-specific IgG1 
(Figure 11A) and IgG2a (Figure 11B) in the serum samples were significantly higher for all 
immunization groups compared to adjuvant alone. While the cognate antigen-specific 
IgG1:IgG2a ratios in mice immunized with rTm-WAP-F8+Na-GST-1 or rTm-WAP49 were 
significantly higher compared to the adjuvant alone, the ratios were lower in mice immunized with 
rTm-WAP-F8+Na-GST-1, relative to that in mice immunized with Tm-ES. However, the 
IgG1:IgG2a ratios in mice immunized with rTm-WAP49 were comparable to that in mice 
immunized with Tm-ES (Figure 11C).  
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Next, we compared the efficacy and immune correlates for rTm-WAP-F8+Na-GST-1 and 
rTm-WAP49 as immunogens using the same immunization and challenge schedule as described 
above. We also included a group of mice immunized with rNa-GST-1 to account for its potential 
contribution to protection observed for rTm-WAP-F8+Na-GST-1. In comparison to the Montanide 
ISA 720 adjuvant control, a significant reduction in worm burden was observed in mice 
immunized with rTm-WAP49 (48%, p=0.000103) or rTm-WAP-F8+Na-GST-1 (38%, p=0.00278), 
as well as the positive control Tm-ES (89%, p<0.0001), with no significant difference between 
Figure 11. Humoral immune responses induced by immunization with rTm-WAP-
F8+Na-GST-1, rNa-GST-1, and rTm-WAP49 proteins in the AKR murine model. Humoral 
immune response was measured by determining the end-point serum titer for antigen-specific 
(A) IgG1and (B) IgG2a by ELISA to calculate the (C) IgG1 to IgG2a ratio for the mice in each 
group. Mice immunized with Montanide ISA 720 adjuvant alone were used as negative 
controls. Statistical significance: *p<0.05, **p<0.01 ***p<0.001, ****p<0.0001. 
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rTm-WAP-F8+Na-GST-1 and rTm-WAP49. Importantly, immunization with rNa-GST-1 did not 
lead to a significant reduction in worm burden after challenge suggesting that the protective 
efficacy for the rTm-WAP-F8+Na-GST-1 was related to the WAP fragment 8, and not the Na-
GST-1 tag (Figure 12).  
 
Immune correlates for the protective efficacy by rTm-WAP49 and rTm-WAP-F8+Na-GST-
1 included significantly higher antigen-specific IgG1 endpoint titers post-infection compared to 
that in mice immunized with the Montanide ISA 720 adjuvant alone (Figure 13A). However, rTm-
WAP-F8+Na-GST-1 generated a higher antigen-specific IgG2a response (Figure 13B), leading 
to a significantly lower IgG1:IgG2a ratio relative to that observed in mice immunized with rTm-
WAP49 (Figure 13C). 
 
 
Figure 12. Efficacy of T. muris egg challenge in mice immunized with Tm-ES, rTm-
WAP49, rTm-WAP-F8+Na-GST-1 or rNa-GST-1. Following the immunization and 
challenge schedule shown in figure 8A, protective efficacy was evaluated on day 15 post-
infection by counting of worms in the intestines by microscopy and compared to that in the 
Montanide ISA 720 control group. 
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We also analyzed post-challenge cellular immune correlates of protection in the spleen, 
the parasite-draining mesenteric lymph nodes (MLNs), and the vaccine-draining inguinal lymph 
nodes (ILNs). In mice immunized with rTm-WAP-F8+Na-GST-1 or rTm-WAP49, stimulation of 
splenocytes with cognate antigen showed high levels of TH2 cytokines IL-4, IL-5, IL-6, IL-9 and 
IL-13 (Figure 14A). In comparing the two WAP derivative TH2 cytokine levels, IL-4, IL-5, and IL-
6 were all produced into the cellular supernatant at similar levels to cognate antigen stimulation 
of splenocytes (Table 5A). Interestingly, we observed that the IL-13 response was significantly 
Figure 13. Post-challenge humoral immune responses in mice immunized with rTm-
WAP49 or rTm-WAP-F8+Na-GST-1. At the time of sacrifice, humoral immune response in 
terms of end-point serum titers for antigen-specific (A) IgG1 and (B) IgG2a were measured 
by ELISA to calculate (C) IgG1 to IgG2a ratio. Mice in groups injected with Montanide ISA 
720 were used as negative controls. Statistical significance: *p<0.05, **p<0.01 ***p<0.001, 
****p<0.0001. 
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higher for rTm-WAP-F8+Na-GST-1 (p=0.01) whereas the IL-9 response was significantly higher 
for rTm-WAP49 (p<0.0001), relative to each other in the splenocytes (Figure 14B) (Table 5A). 
A significant TH2 response was observed in the MLNs of mice immunized with rTm-WAP-F8+Na-
GST-1 or rTm-WAP49 (Figure 14C) compared to mice immunized with ISA 720 adjuvant and 
stimulated with either rTm-WAP-F8+Na-GST-1 or rTm-WAP49, respectively. However, there 
was no significant difference in TH1 or TH2 cytokine levels in the cellular supernatants of MLNs 
stimulated by rTm-WAP-F8+Na-GST-1 or rTm-WAP49 (Figure 14D) (Table 5B). A similar, 
significant TH2 responses was seen in the ILNs of mice immunized with rTm-WAP-F8+Na-GST-
1 or rTm-WAP49 compared to mice immunized with ISA 720 (Figure 14C). Again, there was no 
observed difference in  TH1 or TH2 cytokine levels of ILNs stimulated by rTm-WAP-F8+Na-GST-
1 or rTm-WAP49 (Figure 14F) (Table 5C). 
  
 56 
 
 
 
 
 
 
 
 
 
 
A 
B 
 57 
 
 
 
 
 
 
 
 
C 
D 
 58 
 
 
 
 
 
 
 
 
Figure 14. Post-challenge cellular immune responses in terms of cytokine levels in the 
supernatants of cells stimulated with media or cognate antigens. Cytokines detected in 
the supernatants of (A-B) splenocytes, (C-D) mesenteric lymph nodes (MLNs), or (E-F) 
inguinal lymph nodes (ILNs) after stimulation with media only or cognate antigen, rTm-WAP-
F8+Na-GST-1 (10 μg/mL) or rTm-WAP49 (10 μg/mL) for 72 hours were detected using a 23-
plex assay kit. Cytokines stacked based on TH1 vs TH2 group for each cognate antigen and 
compared to ISA 720 controls stimulated with the corresponding antigen. Mice in groups 
injected with Montanide ISA 720 were used as negative controls. Cells receiving no stimulus 
(media only) were subtracted as background from stimulated cells from corresponding mice. 
Values from duplicate wells for each treatment/stimulation were averaged for individual 
cytokines for the 15 mice in each group to calculate statistical significance. Data are presented 
as means ± 95% confidence interval. Statistical significance: *p<0.05, **p<0.01 ***p<0.001, 
****p<0.0001. Effect size: d<0.2, d<0.5, d<0.8, and d>0.8, correspond to N (negligible), S 
(small), M (medium), and L (large), respectively.  
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Splenocytes 
Mesenteric Lymph Nodes 
Inguinal Lymph Nodes 
Table 5. Analyses of post-challenge TH1 and TH2 cytokine levels in the supernatants 
of cells stimulated with rTm-WAP49 or rTm-WAP-F8+Na-GST-1. Cytokine levels of 
WAP49 (rTm-WAP49) and WAP-F8  (rTm-WAP-F8+Na-GST-1) in (A) splenocytes, (B) 
mesenteric lymph nodes, and (c) inguinal lymph nodes, were compared by Kruskal-Wallis H 
test with Dunn’s Multiple Comparisons. Data are presented as mean. Statistical significance: 
not significant (NS)> 0.05, *p<0.05, **p<0.01 ***p<0.001, ****p<0.0001. 
A 
B 
C 
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Sera from mice immunized with rTm-WAP49 or rTm-WAP-F8+Na-GST-1 recognize native 
Tm-WAP protein 
Serum samples from mice immunized with the various T. muris-derived immunogens 
(rTm-WAP49, rTm-WAP-F8+Na-GST-1, and rTm-CAP-1) were tested for their antibody 
recognition of Tm-ES by ELISA and endpoint titers were determined (Figure 15A). We observed 
that both rTm-WAP49 and rTm-WAP-F8+Na-GST-1 exhibited significantly greater (~100-fold) 
recognition of Tm-ES than rTm-CAP-1. Furthermore, antibody recognition of Tm-ES by rTm-
WAP49 and rTm-WAP-F8+Na-GST-1 were similar to that of Tm-ES antisera, suggesting Tm-
WAP as an immunodominant antigen in the ES products of the T. muris adult worm. We also 
performed western blot analyses of multiple T. muris products using serum samples from mice 
immunized with rTm-WAP49, rTm-WAP-F8+Na-GST-1, or Tm-ES (Figure 15B). We observed 
that mouse anti-Tm-ES serum originally used for the immunoscreening of the T. muris cDNA 
library clearly identified 49kd and 31kd protein bands corresponding to rTm-WAP49 and rTm-
WAP-F8+Na-GST-1, respectively. The mouse anti-rTm-WAP49 sera recognized rTm-WAP49 
and the WAP fragment within rTm-WAP-F8+Na-GST-1, but not the rNa-GST-1 tag. Sera from 
mice immunized with rTm-WAP-F8+Na-GST-1 recognized rTm-WAP49 and rNa-GST-1. 
Importantly, sera from mice immunized with either rTm-WAP49 or rTm-WAP-F8+Na-GST-1 
exhibited a similar recognition pattern of Tm-ES products, with several bands from 28-98 kDa 
range, corroborating findings that highly-conserved WAPs may be expressed as several 
secretory proteins of different molecular weights by both T. muris (127) and T. trichiura (21). 
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Figure 15. Cross-recognition of native and recombinant Tm-WAP and Tm-CAP-1 
proteins. (A) Serum samples from mice immunized with rTm-WAP49, rTm-WAP-F8+Na-
GST-1, and rTm-CAP-1, and Tm-ES were tested for their IgG antibody recognition of Tm-ES 
by ELISA endpoint titers. Statistical significance: *p<0.05, **p<0.01 ***p<0.001, ****p<0.0001. 
(B) Western blot analyses for the serological recognition and cross-recognition of rTm-
WAP49, rTm-WAP-F8+Na-GST-1, and Tm-ES. In each panel, the lane numbers on the top 
represent: (1) SeeBlue pre-stained protein marker; (2) T. muris adult homogenate; (3) T. muris 
ES; (4) Recombinant Tm-WAP49 expressed in P. pastoris; (5) Recombinant Tm-WAP-
F8+Na-GST-1 fusion protein expressed in E. coli; (6) Recombinant Na-GST-1 expressed in 
P. pastoris. The SDS-PAGE was performed using 4-20% gradient NuPAGE/MES gel. The 
blots were incubated with different mouse anti-sera (1:3,000) as shown under each panel. For 
WB with anti-Tm-ES, the loaded amount of protein was adjusted for lane 2 to 6 as 2.0 µg, 500 
ng, 1.0 µg, 400 ng and 400 ng. The nitrocellulose membranes of anti-rTm-WAP-F8+Na-GST-
1 and anti-Tm-ES were cut just prior to ECL substrate reaction between lanes 4-5 and 3-4, 
respectively, to perform different lengths of exposure time to allow for the detection of the 
signal. 
 
 
A 
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Recombinant Tm-WAP protein does not elicit antigen-specific IgE response 
The generation of antigen-specific IgE antibodies secondary to vaccination or pre-existing 
in the population would likely impair the protective efficacy of immunization with that specific 
candidate vaccine (137). In response to a systemic vaccination these circulating parasite-specific 
IgE antibodies, if induced, can lead to a deleterious allergic response, as seen with the hookworm 
Na-ASP-2 vaccine (138). Serum-specific IgE to total IgE ratio is a clinical indicator of allergen-
specific response (139, 140). We observed that vaccination with either rTm-WAP49 or rTm-WAP-
F8+Na-GST-1 did not lead to any significant serum-specific IgE to total IgE ratio compared to 
Montanide ISA 720 (Figure 16). Ratios fell below a cutoff defined by the average values 
observed analyzing serum samples from control group of mice immunized with PBS. Additionally, 
Tm-ES, which contains the immunodominant native Tm-WAP, did not induce an IgE response. 
 
  
Figure 16. Analyses of serum IgE levels in mice immunized with rTm-WAP49 and rTm-
WAP-F8+Na-GST-1. Serum levels of antigen-specific IgE were measured by ELISA and the 
total IgE concentrations were determined using a standard curve and shown as an antigen-
specific IgE to total IgE ratio. Mice vaccinated with Montanide ISA 720 were used as negative 
controls. Cutoff (black dashed line) was defined by the average ratio induced by PBS. 
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3.4 Discussion: 
In this study we demonstrated that Tm-WAP is a TH2 immunogen that is protective 
against T. muris challenge. Immunization with either the near full-length Tm-WAP (rTm-WAP49) 
or Tm-WAP fragment fusion protein (rTm-WAP-F8+Na-GST-1) led to a significant reduction in 
worm burden after T. muris challenge. Interestingly, relative protection after immunization with 
rTm-WAP49, was greater but not significantly different from that observed after immunization 
with rTm-WAP-F8+Na-GST-1.  
Antibody recognition of both rTm-WAP49 protein and the fragment rTm-WAP-F8 by Tm-
ES antisera and the reciprocal recognition of native Tm-WAP in Tm-ES by anti-rTm-WAP49 and 
anti-rTm-WAP-F8+Na-GST-1 sera, suggest that both candidates, as well as Tm-WAP in the Tm-
ES, contain epitopes with conserved antigenicity. 
Critical cellular mediators of protection against T. muris identified in our studies are the 
TH2 cytokines IL-4, IL-9, and IL-13. In this regard, it is well-established that the TH2 cytokine IL-
4 is a critical mediator to enhance antibody responses (87), while IL-13 is recognized for its role 
in promoting worm expulsion through goblet cell expansion, mucin production, and smooth 
muscle hypercontractility (87, 89). Similarly, IL-9 mediates smooth muscle hypercontractility, as 
well as tissue mast cell maturation (88, 89). We identify a strong TH2 response at multiple key 
secondary lymphoid sites, including the parasite-draining MLNs, vaccine-draining ILNs, and the 
spleen. Given the important roles for these TH2 cytokines in the infection process of the worm, 
our results demonstrating the protective immunity elicited by the near full-length recombinant 
WAP protein, or the highly conserved fragment 8 of the WAP, strongly support their potential as 
vaccine candidates.  
In contrast to the protective efficacy of the WAP, Tm-CAP-1, the second most highly 
expressed protein identified in our studies from the excreted-secreted products of T. muris, was 
ineffective in inducing strong type 2 immune response as well as protection. In addition, while 
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antisera from rTm-CAP-1 vaccinated mice did recognize Tm-ES antigen by ELISA, it had nearly 
a 100-fold less recognition relative to either recombinant Tm-WAP protein, which was identical 
to Tm-ES antisera recognition of itself. This is surprising, given that literature reports identify the 
CAP-domain family (also known as SCP/TAPS) as a promising vaccine target due to its 
abundance in the secretome of whipworm and other soil-transmitted helminths (126, 127). 
Additional studies testing different immunization regimens and/or adjuvant formulations should 
inform whether or not the CAP-1 protein can induce TH2 immunity and protective efficacy. 
However, since rTm-CAP-1 protein was not found to be protective in our murine model, it was 
not included for the detailed biophysical characterization (Chapter 4) or evaluation of human 
immune recognition of protective T. muris protein(s).  
Pre-formed IgE antibodies to recombinant Na-ASP-2 in vaccine recipients from 
hookworm endemic regions are thought to have induced generalized urticaria, halting the 
vaccine’s development (141). In this regard, after three immunizations with either of the two 
recombinant WAP proteins we did not observe the parasite-specific IgE to total IgE ratio to be 
above background levels. Future studies evaluating the potential of the recombinant WAP 
proteins as vaccine candidates should determine whether natural infection with T. trichiura 
generates pre-formed IgE antibodies that recognize the recombinant Tm-WAP proteins. 
In summary, we have developed two recombinant derivatives of Tm-WAP, rTm-WAP-
F8+Na-GST-1 and rTm-WAP49, which are both protective in the AKR animal model. 
Furthermore, we demonstrate that both proteins generate a strong type 2 immune response, 
similar to the highly protective Tm-ES. Future evaluations will require verification that Na-GST-1 
fused with Tm-WAP-F8 retains protective efficacy as an individual candidate against hookworm, 
supporting the potential to developing pan-anthelminthic vaccine (108, 142, 143).  
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Chapter IV 
Characterization and localization of protective T. muris proteins.  
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4.1 Introduction 
As described in chapter II of this dissertation, we identified candidate antigens by 
screening the T. muris cDNA library with protective sera generated against Tm-ES. Using a 
whipworm animal model, we immunized mice with candidate antigens to evaluate immunity, as 
well as protection against subsequent T. muris challenge infection (Chapter III). Data from these 
studies identified Tm-WAP, derived from the Tm-ES, as a strong TH2 immunogen that elicits 
protection when administered as a recombinant near full-length (rTm-WAP49) or fragment-fusion 
protein (rTm-WAP-F8+Na-GST-1) co-formulated with Montanide ISA 720 adjuvant. Based on 
these promising results, we designed a series of analytical studies to determine the stability, 
homogeneity, and purity of rTm-WAP49 and rTm-WAP-F8+Na-GST-1 (Figure 17). Here we 
show that both these recombinant forms of Tm-WAP exhibit high degree of thermostability and 
are homogeneous with one major peak by ultra performance liquid chromatography (UPLC). 
Sequence analysis of Tm-WAP revealed that it was likely a secretory protein (Chapter II). 
Given that Tm-WAP was identified through screening with Tm-ES, we hypothesized that Tm-
WAP was secreted from the stichosome of T. muris. To test this hypothesis, we employed 
antiserum from mice immunized with rTm-WAP49 for immunofluorescence analyses of cecum 
tissue sections from mice infected with T. muris. We observed that antiserum from mice 
immunized with rTm-WAP49 localized the native WAP to the stichosome of T. muris within the 
infected mouse cecum tissues.  
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4.2 Materials and Methods 
Immunofluorescence staining of mouse cecum  
Immunofluorescent staining for Tm-WAP in adult Trichuris muris was performed using 
the M.O.M.™ Immunodetection Kit (Vector Labs, USA). In brief, SCID mice were sacrificed on 
day 42 post T. muris infection. Intestinal tissue with worms embedded were fixed in paraffin and 
sectioned. Primary staining was performed with PBS, naïve sera (1:100), or anti-rTm-WAP49 
(1:100). Secondary staining was with FITC-conjugated goat anti-mouse IgG (1:500). For staining 
the cellular nuclei DAPI was embedded in the mounting medium.  
Circular Dichroism  
Circular dichroism (CD) spectra were used to predict the secondary structure of rTm-
WAP49, rTm-WAP-F8+Na-GST-1 and rNa-GST-1. Samples were prepared at a protein 
concentration of 0.02 mg/mL in 10 mM phosphate buffer. The CD spectra were recorded with a 
Jasco J-1500 s spectrophotometer (Jasco Inc., USA), scanning from 190 nm to 300 nm at 
50 nm/min with a bandwidth of 1 nm and response time of 1 second. Experiments were 
performed using a quartz cuvette with a path length of 1 cm at 25 °C. Six scans were averaged 
and compared to a baseline of buffer-only sample. CDPro software (Colorado State Univ., USA) 
was used to predict secondary structure against reference sets SP43, SDP48 and SMP56 and 
analyzed by CONTIN and CDSSTR, as previously described (144).  In addition, CD spectra were 
collected as a function of temperature to determine the thermodynamics of protein unfolding. The 
samples were heated form 25°C to 90°C increasing the temperature stepwise at 1°C/data point. 
Each data point was determined as the average of two scans. 
Ultra performance liquid chromatography 
Ultra performance liquid chromatography (UPLC) was used to determine the size of the 
proteins in solution. The system consisted of a Waters ACQUITY UPLC® system with PDA 
detector (Waters, USA) fitted with an ACQUITY UPLC Protein BEH SEC 200Å column, designed 
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to characterize proteins ranging in molecular weight from 10 kDa–450 kDA. We used 2μg each 
of rTm-WAP49, rTm-WAP-F8+Na-GST-1 and rNa-GST-1 to inject into a TSK gel Super SW2000 
column (TOSOH Biosciences, USA) and eluted at 0.3 ml/min isocratically with PBS (pH 7.4) for 
9 min. Absorbance was continuously measured at 220 nm. A gel filtration protein standard 
(BioRad, USA) was used to generate a calibration curve. The standard includes 5 globular 
proteins: Thyroglobulin (bovine), Gamma globulin (bovine), Ovalbumin (chicken), Myoglobin 
(horse), and Vitamin B12, with respective MW of 670 kDa, 158 kDA, 44 kDa, 17kDa and 1.35 
kDa.  
High performance liquid chromatography with fractional collection 
High performance liquid chromatography (HPLC) was used to collect fractions of the 
different sizes of rTm-WAP49. The system consisted of an Agilent 1260 Infinity series HPLC, 
coupled with a UV detector (Agilent, USA), and a 1260 Infinity II Analytical-Scale Fraction 
Collector (Agilent). An aliquot of 200μg of rTm-WAP49 was injected into a TSK gel Super 
SW2000 column (TOSOH Biosciences, USA) and eluted at 0.5 ml/min isocratically with PBS 
pH 7.4 for 35 min. After 10 min all fractions of 250µL were collected in a 96-well plate. 
Antibody analysis 
Serum samples from mice immunized with Tm-ES and rTm-WAP49 were prepared from 
blood by centrifugation in serum-separating tube (Sarstedt, Germany) at 10,000 g for 5 minutes 
and stored at -80°C until assay. Samples were evaluated for antigen-specific immunoglobulins, 
IgG1 and IgG2a (Lifespan Biosciences, USA) by a modified indirect enzyme-linked 
immunosorbent assay (ELISA), as described previously (131). Concentration of rTm-WAP49 
(0.375 µg/mL) used for ELISA was selected based on pretested optimal signal/noise ratio. The 
fractionally-collected rTm-WAP49 was quantified by NanoDrop A205 Protein Quantifiaction 
(Thermo Fisher Scientific, USA) and used at 0.375 µg/mL to coat the ELISA plates. Antibody 
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absorbance was measured by dual wavelength analysis at test wavelength of 450 nm and the 
reference wavelength of 630 nm using a spectrophotometer (BioTek, USA). 
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4.3 Results 
Native Tm-WAP protein localizes to the stichosome organ of T. muris 
Over the past 20 years, the Trichuris spp. stichosome has been of particular interest due 
to its pathogenic role in facilitating intercellular existence within the host intestinal epithelial layer 
(1, 14, 21, 145). To determine whether Tm-WAP is stichosome-derived, we used anti-rTm-
WAP49 mouse sera to perform fluorescent immunohistochemistry (IHC) of adult T. muris 
embedded in the caecal tissue of SCID mice on day 42 post-infection with 300 embryonated 
eggs (visualized by DAPI nuclear stain). Tissue cross-sections revealed an anti-Tm-WAP 
staining in the tissue-embedded stichosome of T. muris (Figure 17) with no discernable staining 
in the posterior, non-stichosome end of the worm. A predominance of the staining occurred in a 
ring-like, granular pattern (red arrow, Figure 17C) beneath the cuticle of the helminth. Directly 
adjacent to the outer layer of the helminth cuticle, we observed strong anti-Tm-WAP binding 
(white arrow, Figure 17C), suggesting secretion of the WAP protein into the mouse caecal 
intraluminal space. Of note, in certain cross sections, there were delineated structures with 
granular anti-Tm-WAP staining (yellow arrow, Figure 17B) within the stichosome. A similar 
pattern of variable distribution of antigen-specific secretory granules was previously described in 
the stichosome of T. spiralis (146). 
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Structure analysis and stability of recombinant Tm-WAPs 
Far-UV circular dichroism (CD) was used to determine the secondary structural 
components of rTm-WAP49 and rTm-WAP-F8+Na-GST-1. The rNa-GST-1 tag protein, which 
comprises 80% of the WAP fragment fusion protein (rTm-WAP-F8+Na-GST-1) and has been 
extensively biophysically characterized as hookworm vaccine candidate, was evaluated as a 
control (108, 142). Different secondary structural features, such as α-helices, beta-pleated 
sheets, and turns/loops, can be interpreted from characteristic positive and negative bands along 
the CD spectra (147–149). Additionally, given that protein structure is dependent on its 
environment, temperature, stability, and excipient (small molecule) interactions can be evaluated 
using CD (150). 
The CD analyses revealed that rTm-WAP49 consists of 65% turns and loops, 30% beta-
pleated sheets, and 5% α-helices (Figure 18). These values differ significantly from the predicted 
secondary structure by Phyre2, a protein modeling and prediction software (151), which 
projected 94% turns and loops, 0% beta-pleated sheets and 5% α-helices. The rTm-WAP-
F8+Na-GST-1 protein, on the other hand, is comprised of 28% turns and loops, 13% beta-pleated 
sheets, and 59% α-helices by CD, which overlaps considerably with the predicted Phyre 2 
structure, at 34%, 7%, and 59%, respectively. The rNa-GST-1 tag protein had similar secondary 
structure as rTm-WAP-F8+Na-GST-1, with 16% turns and loops, 12% beta-pleated sheets, and 
72% α-helices by CD, and a similar 28%, 10%, 62%, respectively, Phyre2 structural prediction.  
Figure 17. Immunofluorescent staining of Tm-WAP expressed in adult Trichuris muris 
stichosome. (A) Cross-sections of murine cecum embedded with multiple adjacent adult T. 
muris at 20x magnification. (B) Sections of embedded T. muris showing Tm-WAP recognition in 
a distinct granular pattern within a discernable internal structure (yellow arrow). (C) The orange 
box in (A) was imaged at 40x magnification. Most embedded T. muris revealed Tm-WAP 
recognition in a ring pattern adjacent to the cuticle of the helminth (red arrow) with presumptive 
Tm-WAP secretions into the caecal lumen (white arrow). Primary staining was performed with 
PBS, naïve sera (1:100), or anti-rTm-WAP49 (1:100). Secondary staining was with FITC-
conjugated goat anti-mouse IgG (1:500). The nuclear stain DAPI was embedded in the 
mounting medium. SCID mice were infected with T. muris for 42 days. 
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 To evaluate the denaturation characteristics of rTm-WAP49 and rTm-WAP-F8+Na-GST-
1 proteins by CD, the molar ellipticity at 208 nm was measured over an increasing temperature 
range from 25 to 83°C, as previously described (152). The data was normalized between 1 
(folded) and 0 (unfolded) is presented in Figure 19.  Data was normalized as follows: 
 
Figure 18. Secondary structural components of rTm-WAP49, rTm-WAP-F8+Na-GST-1, 
and rNa-GST-1. Circular dichroism (CD) spectra were scanned from 190 nm to 300 nm at 
constant temperature of 25 °C. Secondary structure was predicted using the CDPro software 
by comparing with three reference sets (SP43, SDP48 and SMP56) and using two data fitting 
programs (CONTIN and CDSSTR) and grouped into the categories helices, beta sheets, and 
turns and loops. Experimental CD data was compared to Phyre 2 predicted structure based 
on amino acid sequence. 
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Relative CD =( |Y[θ] exp| - |Y[θ] min| ) / ( |Y[θ] max| - |Y[θ] min| ) 
 
Where Y[θ]exp  is the experimental molar ellipticity (degrees x cm2/ dmol), and Y[θ] min and Y[θ] max 
represent the minimum and maximum molar ellipticity, respectively. As described earlier, rNa-
GST-1  serves as a control reagent. All proteins were evaluated in phosphate buffered saline 
(PBS) at a concentration of 0.02 mg/ mL for both rNa-GST-1 and rTm-WAP-F8+Na-GST-1 had 
a melting temperature of 55°C and 58°C, respectively. The rTm-WAP49 proteins, however, had 
remarkable thermostability with a melting temperature of 75°C. The sharp denaturation of rTm-
WAP49 and rTm-WAP-F8+Na-GST-1 is indictive of a single, well-defined low energy state that 
keeps the protein folded. 
 
Figure 19. Thermodynamics of protein unfolding of rTm-WAP49, rTm-WAP-F8+Na-
GST-1, and rNa-GST-1. The samples were heated form 25°C to 90°C increasing the 
temperature stepwise at 1°C/data point and measured at 208 nm. Each data point was 
determined as the average after two scans.. 
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Analysis of purity, sizing, and homogeneity of recombinant Tm-WAPs 
 To evaluate the biophysical integrity of rTm-WAP49 and rTm-WAP-F8+Na-GST-1 in 
solution, we used gel filtration liquid chromatography (LC) to study the size distribution of the 
proteins (153, 154). We initially characterized the recombinant Tm-WAPs by ultra performance 
liquid chromatography (UPLC) using an ACQUITY UPLC Protein BEH SEC 200Å column, which 
is optimized to separate proteins between 10 kDa–450 kDA. A molecular weight standard was 
run over the column, to create a calibration curve and rNa-GST-1 served as a continued protein 
of comparison to rTm-WAP-F8+Na-GST-1.  By UPLC, rNa-GST-1 was a dimer protein, with a 
sharp single peak at molecular weight 43 kDA (rNa-GST-1 “a”, Figure 20) confirming previous 
reports (155). As can be expected, the main peak of the chromatogram of rTm-WAP-F8+Na-
GST-1 (rTm-WAP-F8+Na-GST-1 “b”, Figure 20) is eluting only slightly earlier and has an 
estimated molecular weight of 51 kDA. As can be observed, the peak width of rTm-WAP-F8+Na-
GST-1 is wider than the peak of rNa-GST-1, which is not unusual for a fusion protein. rTm-
WAP49, on the other hand, showed multiple large peaks at (“a”) 210 kDa, (“b”) 65 kDa, and (“c”) 
3.4 kDa (rTm-WAP49, Figure 20), suggestive of either protein oligomerization or aggregation. 
However, it should be noted that, due to the lack of any aromatic amino acids (tryptophan or 
tyrosine) in the WAP fragment, all samples were measured using UV absorption at 220nm. At 
this wavelength any possible trace amounts of chromophores or organic compounds (e.g. amino 
acids) from the production process can be detected, likely causing peak “c” at 3.4 kDa. They are 
not likely due to protein degradation, as fractionally collected peak “c” did not show any protein 
bands by Coomassie staining on SDS PAGE. 
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To further evaluate the multiple peaks identified in the rTm-WAP49, the protein was 
denatured by sodium dodecyl sulfate and separated by molecular weight using polyacrylamide 
gel electrophoresis (SDS-PAGE) and stained by Coomassie Brilliant Blue (Figure 21), as 
previously described (156). rTm-WAP49 reduced with 2-Mercaptoethanol (lanes 3-4), reveal a 
Figure 20.  UPLC size characterization of rTm-WAP49, rTm-WAP-F8+Na-GST-1, and 
rNa-GST-1. 2μg of  each antigen was injected into a TSK gel Super SW2000 column and 
eluted at 0.3 ml/min isocratically with PBS (pH 7.4) for 9 min. Absorbance was continuously 
measured at 220 nm. Molecular weight standard (MWS) was used (bottom figure) and peaks 
a, b, c, d, and e, correspond with respective MW of 670 kDa, 158 kDA, 44 kDa, 17kDa and 
1.35 kDa 
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single 49 kDa smeared protein. The non-reduced rTm-WAP49 reveal 3 distinct bands between 
62 and 188 kDa.  
 
 
 To determine whether the multiple rTm-WAP49 peaks found by UPLC and visualized by 
SDS-PAGE were due to protein instability, rTm-WAP49 was fractionally collected by size-
exclusion high performance liquid chromatography (HPLC) between 1A through 8H. Size-
exclusion HPLC is similar to the chromatogram of the size-exclusion UPLC assay, with a slightly 
lower resolution, but connected to a fraction collector. Based on a gel filtration MW standard 
curve, fractions 7B, 6A, and 5A relate to protein samples with average respective molecular 
weights of 49 kDa, 96 kDa, and 147 kDa (Figure 22A). After collection of multiple fractions 7B, 
6A, and 5A, they were re-run through the HPLC, and were found to have solitary peaks, 
Figure 21. Multiple protein bands of non-reduced rTm-WAP49. In each panel, the lane 
numbers on the top represent: (M) SeeBlue pre-stained protein marker; (1-2) BSA control at 
1 µg and 2 µg; (3-4) reduced recombinant Tm-WAP49 at 1 µg and 2 µg; and (5-6) non-
reduced recombinant Tm-WAP49 at 1 µg and 2 µg. The SDS-PAGE was performed using 4-
20% NuPAGE/MES gel and stained with Coomassie Brilliant Blue. 
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suggesting that individual fractions were stable in various oligomer states, likely as a monomer, 
a dimer, and a trimer state, and did not further aggregate. Fractions 4A through 7D were 
evaluated for variations in immune recognition. Serum generated by mice immunized with rTm-
WAP49 showed equal recognition of the various fractions and unfractionated rTm-WAP49 
(Figure 22B). Serum generated by mice immunized with Tm-ES, however, had increasing 
recognition with as the fraction size increased (Figure 22C).   
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Figure 22. Fractional collection of different size rTm-WAP49 and their conserved 
recognition by rTm-WAP49 and Tm-ES antisera. (A) High performance liquid 
chromatography (HPLC) was used to collect varying sizes of rTm-WAP49 between fractions 
4A and 7D (top). Fractions 7B, 6A, and 5A were reanalyzed by HPLC (middle) and sized by 
molecular weight using a Bio-Rad protein gel standard (bottom). (B) rTm-WAP antisera and 
(C) Tm-ES antisera were used to evaluate immune recognition of rTm-WAP49 fractions. Total 
IgG was measured by ELISA at plotted based on optical density (OD). Unfractionated rTm-
WAP49 was used as a positive control antigen and baseline, and naïve sera from 
unvaccinated mice was used a negative control. 
B 
C 
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4.5 Discussion 
Using rTm-WAP49 antisera, native Tm-WAP protein was localized to the stichosome 
organ of T. muris.  Protection generated in mice immunized against Tm-WAP further supports 
previous studies suggesting that the stichosome plays a critical role in helminth pathogenicity 
(70, 71). The homologous stichosome-derived secretory Trichuris trichiura WAPs, Tt52 and Tt95, 
have been described for their ability to generate pores in a planar lipid bilayer (21–23). Future 
studies testing the ability of Tm-WAP antisera to inhibit pore-formation, preventing stichosome 
penetration and maintenance in the colonic mucosa would be important to further delineate the 
mechanism underlying the protective efficacy observed for the recombinant Tm-WAP.  
To evaluate the protein characteristics and stability of rTm-WAP-F8+Na-GST-1 and rTm-
WAP49, we conducted a biophysical assessment of both candidates using multiple analytical 
techniques such as SDS-PAGE, circular dichroism (CD), and liquid chromatography. 
Collectively, this data will provide specific information concerning the physical state of each 
protein, creating a baseline for further stability testing. 
We observed that rTm-WAP-F8+Na-GST-1 shared biophysical characteristics of both 
rTm-WAP49 and rNa-GST-1. Since rTm-WAP-F8+Na-GST-1 is 80% composed of Na-GST-1, 
unsurprisingly, all biophysical characteristics we measured had greater similarity to rNa-GST-1. 
By CD, the secondary structure of rTm-WAP-F8+Na-GST-1 revealed it was primarily composed 
of α-helices, like rNa-GST-1. However, rTm-WAP-F8+Na-GST-1 did retain the characteristic of 
additional turns and loops, as seen with rTm-WAP49. When evaluating the thermodynamics of 
protein unfolding by CD, rTm-WAP-F8+Na-GST-1 exhibited a slightly increased melting 
temperature compared to rNa-GST-1. Characterization by UPLC further supported that rTm-
WAP-F8+Na-GST-1 shared high similarity with rNa-GST-1. Overall, the highly conserved 
biophysical properties between rTm-WAP-F8+Na-GST-1 and rNa-GST-1, coupled with the 
conserved antigenicity by western blot, suggest that rTm-WAP-F8+Na-GST-1 may retain enough 
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protein similarity to vaccine candidate rNa-GST-1 (108), to have conserved cross-protection 
against hookworm challenge.  
By CD, the secondary structure of rTm-WAP49 revealed it was primarily composed of 
turns and loops, followed by beta-sheets. Interestingly, rTm-WAP49 had remarkable 
thermostability, with a melting temperature of 75°C, and uniformity with a sharp denaturing curve. 
The high stability is probably associated with the disulfide core domain of the whey acidic protein 
family. Given that  Tm-WAP was identified from among the excreted-secreted products of T. 
muris, and our fluorescent immunohistochemistry analyses suggested secretion into the colonic 
mucosa, extreme protein stability may be necessary for preserved function in the harsh intestinal 
environment. By UPLC, at 220nm, rTm-WAP49 showed varying size between 65kDa and 210 
kDa. Given the single band seen by SDS-PAGE when reduced and denatured, along with the 
sharp denaturing curve by CD, we suspect that rTm-WAP49 exists in multimers. Fractions 
collected by HPLC showed sharp protein peaks of each fragment when retested on HPLC. This 
indicates protein oligomerization, as opposed to uncontrolled protein aggregation due to 
instability. With 43 cysteine residues in the protein, one possibility is disulfide bond formation 
leading to a mix of monomeric, dimeric, and trimeric species. To determine whether or not this 
affected immunogenicity, we tested fractions for recognition by IgG from mice immunized with 
unfractionated rTm-WAP49 or Tm-ES. There was no difference in recognition by rTm-WAP49 
antisera compared to naïve sera. While all rTm-WAP49 fractions were recognized by Tm-ES 
antisera, compared to naïve sera, there was an increased recognition of larger, multimeric 
fractions. Interestingly, in Chapter III we demonstrated that a western blot of Tm-ES with rTm-
WAP49 antisera reveals multiple bands with cross recognition. This suggests that native T. muris 
WAP may exist as multimers or conserved gene duplications, similar to that reported for T. 
trichiura WAP (21). Nonetheless, rTm-WAP49 may need to be re-formulated or re-engineered to 
evaluate the role of multimers on immunogenicity and efficacy. 
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Chapter V 
In vitro evaluation of human immune recognition for the T. muris 
recombinant proteins exhibiting protective efficacy  
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5.1 Introduction 
The ultimate goal of the research presented in this dissertation was to identify candidate 
T. muris antigens protective in an animal model and to explore immune mechanisms of 
protection. Given the immunogenicity and protective efficacy of Tm-WAP demonstrated from 
data presented in Chapters II and III of this dissertation, we explored the translational potential 
by testing immune recognition of Tm-WAP by serum and T cells from patients previously infected 
with T. trichiura. To achieve this, we implemented a cross-sectional human study of 236 healthy 
volunteers between the ages of 13 and 45 years from the rural region of Honduras. This age 
range was selected based on epidemiological data suggesting increased protection from 
trichuriasis (157). While prevalence of disease remained constant after 1 year of age, the worm 
burden, and subsequent associated morbidity, dramatically decreases beginning in early 
adolescence (157). This finding suggests that although the risk of exposure does not decrease 
with age, beginning in adolescents, the infected host is better able to control infection. We 
hypothesize this is due, at least in part, to an immune mediated mechanism of protection after 
multiple early exposures to the parasite.   
Honduras is a low middle-income nation in Central American nation that is endemic with 
high rates of soil-transmitted helminths (STHs). Mass drug administration (MDA) in Honduras is 
conducted almost exclusively through the primary school system, providing coverage to nearly 
70% of children in school (158). However, given the combination of the particularly low efficacy 
of MDA drugs against trichuriasis (106), the inability of the Honduran government to co-
implement aggressive sanitary infrastructure (158), and the nearly 20% of students who drop-
out of primary school in Honduras by the age of 15 and do not receive MDA (159), T. trichiura is 
still highly endemic in Honduras. This is particularly true in the rural regions of Honduras, which 
led us to selecting the remote area in and around the province of Colomoncagua, within the 
Department of Intibucá.  
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The first goal of the study was to identify the active prevalence of trichuriasis in the region, 
which has not been reported in this area to our knowledge. The second objective was to use 
serum samples and peripheral blood mononuclear cells (PBMC) from participants to determine 
immune recognition of rTm-WAP49 from this endemic region. 
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5.2 Materials and Methods 
Ethics statement 
All human sample collection in Honduras was conducted in accordance with University 
of Texas Health Science Center at Houston Institutional Review Board (IRB) (approved protocol 
HSC-MS-14-0035), Baylor College of Medicine IRB (approved protocol H-33704) and the 
National Autonomous University of Honduras (UNAH) Committee of Ethics Investigation 
(approved protocol No. 01-2014).  Non-endemic control serum samples from participants living 
in the United States of America (USA) were collected and used in accordance with Baylor College 
of Medicine IRB (approved protocol H-35471). All human research was conducted in compliance 
with applicable United States and Honduran federal statutes and regulations relating to human 
research.  
Study Population 
We originally enrolled 30 adolescents (ages 13-17) and 53 adults (ages 18-45) in the 
municipality of Colomoncagua. Of these, 3 adults (age 45+) were discovered later to be outside 
the inclusion criteria for age range, and were removed from the study after being notified, and 
reported to the IRB. Subsequently, we enrolled an additional 83 adolescents and 73 adults. 
Together, the 113 adolescents and 123 adults constitute the 236 total participants evaluated in 
the study.  
Inclusion Criteria: 
Any adolescent (13-17) or adult (18-45) living within the municipality of Colomoncagua, 
deemed medically fit to donate stool and blood samples, was included after informed 
consent/assent was obtained. 
Exclusion Criteria: 
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Any person given deworming medication (albendazole, mebendazole, levamisole, and 
pyrantel pamoate) in the past 6 months was excluded. Non-healthy participants, with the 
exception of symptoms related to a gastrointestinal parasitic infection, determined by one of our 
physicians, was excluded and instead offered medical evaluation separate to this research study 
by clinic staff. Pregnant women were excluded from the study. Given that a 10mL blood draw 
and providing a stool sample has little medical risk to the mother or fetus, as well as no effect on 
the study, questioning the female participant about their pregnancy status was ethically and 
medically sufficient as a means of exclusion. 
Community leaders within the town of Santa Ana, where the Houston Shoulder to 
Shoulder Clinic is located, and surrounding communities within Colomoncagua were contacted 
at the outset for their interest in participating in the study. Adults aged 18-45 years were asked 
to sign a consent form and adolescents aged 13 to 17 years were asked to provide assent with 
their parent or guardian singing a consent form, all in Spanish.  
Sample collection and processing 
 Approximately 50g of fresh stool from each subject was used for DNA extraction by a 
modified MP FastDNA for Soil Kit (MP Biochemicals, USA), as previously described (160). 50 ul 
of extracted DNA samples were stored at -20°C until experimental analysis. 2 mL of blood were 
obtained by venipuncture into sodium heparin collection tubes (BD, USA) and immediately 
centrifuged at 10,000 g for 5 minutes to collect approximately 1 mL of serum and stored at -80°C 
until analysis. Due to the logistic difficulties associated with the limited resource setting, only 68 
participants in 2016 were selected for peripheral blood mononuclear cells (PBMC) isolation. 
PBMCs were freshly isolated by Ficoll-Paque separation technique from approximately 8 mL of 
venous blood in sodium heparin collection tubes (BD, USA), as previously described (161), and 
stored as aliquots of 5-7 million cells per mL in freezing media (90% heat inactivated FBS [VWR, 
Radnor, PA] + 10% DMSO [Corning, USA]) at -80°C until experimental analysis. 
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 Non-endemic serum samples from participants living in the USA were used as a negative 
control for antibody analysis. A total of 95 age-matched participants with no travel history to 
Trichuris endemic regions were selected among the -80°C banked samples.  
Real-time Polymerase Chain Reaction Assay 
 Species-specific primers and TaqMan MGB probes (Thermo Fisher Scientific, USA) were 
used for the PCR analyses of DNA from the stool samples to determine the prevalence of 
helminths species: Trichuris trichiura, Ascaris lumbricoides, Ancylostoma duodenale, Necator 
americanus, Strongyloides stercoralis, and intestinal protozoal species Cryptosporidium 
parvum/hominis, Giardia lamblia, and Entamoeba histolytica. Primer sequences and detailed 
methodology were previously described (160). 
Antibody analysis 
Serum samples were evaluated in triplicate for antigen-specific immunoglobulins IgG 
(Lifespan Biosciences, USA) and IgE (Thermo Fisher Scientific, USA) by a modified indirect 
enzyme-linked immunosorbent assay (ELISA), as described previously (131). The individual 
wells of the ELISA plate were coated using a concentration of rTm-WAP49 at 0.375 µg/mL that 
was selected by pretesting for optimal signal/noise ratio. The absorbance was measured by dual 
wavelength analysis at test wavelength of 450 nm and the reference wavelength of 630 nm using 
a spectrophotometer (BioTek, USA). 
Cytokine analysis  
For the analyses of antigen-specific cytokine production, the frozen samples of PBMCs 
were first thawed in a 37˚C water bath and washed in complete RMPI medium (RPMI 1640 with 
L-glutamine [VWR, USA], 10% heat inactivated FBS [VWR, Radnor, PA], and 1x pen/strep 
solution [Thermo Fisher Scientific, USA]) to remove residual DMSO. Subsequently, the PBMCs 
were resuspended in complete RMPI medium and incubated for 2 hours at 37°C before 
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determining the number of live cells using a Cellometer Auto 2000 Cell Viability Counter 
(Nexelcom, USA).  
 Cells were seeded in a 96-well U-bottom culture plate (Corning, USA) at 1x106 cells per 
well in 250 μl medium and restimulated with either rTm-WAP49 or Tm-ES at varying 
concentration at 37°C, 5% CO2 for varying time points. An unstimulated, media only negative 
control and a positive control stimulation with a mixture of 20 ng/mL PMA and 1 μg/mL Ionomycin 
were performed concurrently. Stimulated cells were pelleted by centrifugation at 300 x g for 5 
min and the supernatants were collected for measuring cytokine production by Luminex analysis, 
as previously described (133), and cells were stained with fluorochrome-conjugated antibodies 
(Table 6) for determining cellular phenotype and function by flow cytometry analysis on the 
Attune NxT Flow Cytometer, as previously described (162).  
 
 
 
 
 
 
 
 
 
 
Target Fluorochrome Vendor (catalog #) 
Viability Live/Dead Near IR Thermo Fisher (L23105) 
CD3e Pacific Blue Biolegend (300330) 
CD4 FITC eBioscience (11-0048-42) 
CCR7 (CD197) PerCP-Cy5.5 RnD (L23105) 
CD45RA Alexa Fluor 700 Biolegend (304120) 
CD25 PE/Dazzle 594 RnD (FAB197T-025) 
IL-4 Brilliant Violet 605 Biolegend (500828) 
IL-5 APC Biolegend (504306) 
IL-13 PE-Cy7 Biolegend (501914) 
IFN-y Brilliant Violet 711 BD (564793) 
FoxP3 PE eBioscience (12-4776-42) 
Ki-67 Brilliant Violet 510 Biolegend (50518) 
Table 6. List of fluorochrome-conjugated antibodies used for flow cytometry of human 
samples. 
 89 
 
5.3 Results 
 Across two collection time points, we enrolled 236 participants between 13 and 45 years 
of age within the province of Colomoncagua, Honduras. Participants across 7 towns were 
characterized based on demographics, hematocrit (%), and relevant gastrointestinal (G.I.) 
symptoms (Table 7). The average age of participation was 23.2 with nearly 60% females. 
Overall, participants had normal hematocrits, with the average at 42.3%. However, over 40% of 
otherwise healthy volunteers had complaints of G.I. pain, with a subsequent 14% reporting 
diarrhea and 9% reporting constipation. Overall, there was not considerable difference in 
population characteristics or demographics across the towns in the province of Colomoncagua. 
 
 
 
Characteristic 
Callejones 
(n = 6) 
Colomoncagua 
(n = 92) 
El 
Carrizal 
(n = 17) 
El 
Hondable 
(n = 8) 
Llano 
Grande 
(n = 11) 
San 
Antonio 
Vados  
(n = 20) 
Santa 
Ana 
(n = 82) 
 
Total 
(n = 236) 
Sex         
     Male 1 39 6 5 5 7 26 89 
     Female 5 53 11 3 6 13 56 147 
Age (years) 14.0 19.3 25.6 21.6 22.1 22.1 25.9 23.2 
Hematocrit (%) 43.8 43.8 41.8 41.4 43.1 43.1 40.6 42.3 
G.I. symptoms         
     G.I. pain (%) 50% 38% 30% 60% 43% 60% 28% 44% 
     Diarrhea (%) 33% 10% 20% 20% 0% 15% 3% 14% 
  Constipation (%) 17% 7% 10% 20% 0% 10% 3% 9% 
Table 7. Demographic data and gastrointestinal symptoms of 236 participant in the 
province of Colomoncagua, Honduras.  Demographic and basic questionnaire data was 
collected on healthy participants ages 13-45 years old across 7 towns within Colomoncagua. 
Sex, age, and hematocrit were measured for all 236 participants. Gastrointestinal (G.I.) 
symptoms questionnaire was only performed among the 156 participants recruited in 2016. 
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Prevalence of trichuriasis and other gastrointestinal parasites in study population 
 Fresh stool samples from participants were stored at 4°C and processed within 24hrs of 
collection. Extracted DNA from approximately 50g of stool was examined for parasite-specific 
DNA by qPCR. We analyzed for the 8 of the most common human G.I. parasites worldwide (160), 
including 5 helminths (trichuriasis, ascariasis, hookworm (both N. americanus and A. duodenale), 
as well as 3 protozoans (cryptosporidiosis, giardiasis, and amebiasis). Nearly 50% of the study 
population was infected with one or more screened G.I. parasites (Figure 23). To our surprise, 
only about 2% of participants were actively infected with T. trichiura. Reported prevalence in 
children in the surrounding areas is as high as 20% (158). Ascariasis and hookworm, on the 
other hand, had approximately 14% and 10% prevalence among participants.  
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Figure 23. Prevalence of 8 of the most common gastrointestinal parasites, including 
Trichuris trichiura, in the province of Colomoncagua, Honduras. Parasite DNA extracted 
from the stool of participants was measured by qPCR.  
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Serological recognition of rTm-WAP49  
After confirming active transmission of T. trichiura within Colomoncagua, we set out to 
measure serological recognition of rTm-WAP49. To date, there are no commercially available 
specific serological tests for T. trichiura. To validate true reactivity, we used non-endemic serum 
from 95 age-matched individuals from USA with no travel history to whipworm endemic regions. 
Serum-specific IgG of rTm-WAP49 (0.375 ug/mL) was measured for each sample, in triplicate, 
and plotted based on the degree of recognition on a histogram (Figure 24A). We identified a 
statistically significant difference (p<0.0001) in mean IgG recognition between the two 
populations as measured by ELISA. (Figure 24B).  
To evaluate humoral allergenicity, we screened for serum-specific IgE recognition of rTm-
WAP49 (0.375 ug/mL) between the two populations and plotted along a histogram (Figure 25A). 
There was no statistically significant difference (p=0.1717) between the Honduras population and 
the non-endemic USA population (Figure 25B). 
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Unpaired t test with Welch's correction  
P value <0.0001 
P value summary **** 
Significantly different (P < 0.05)? Yes 
One- or two-tailed P value? Two-tailed 
Welch-corrected t, df t=9.515 df=256.3 
  
How big is the difference?  
Mean ± SEM of USA (Control) Population 0.6476 ± 0.05686, n=95 
Mean ± SEM of Honduran Population 1.393 ± 0.05395, n=236 
Difference between means 0.7458 ± 0.07839 
95% confidence interval 0.5914 to 0.9002 
Figure 24. Total IgG sera recognition of rTm-WAP49. (A) Participants from the Trichuris 
trichiura endemic region of Colomoncagua, Honduras (n = 236) and compared to non-
endemic, non-travelled, age-matched controls from the USA (n = 95). Results are plotted on 
a histogram based on the degree of total IgG recognition of rTm-WAP49 (0.375 ug/mL) by 
ELISA.(B) Unpaired t test with Welch’s correction comparing the IgG means of the two 
populations. Statistical significance: *p<0.05, **p<0.01 ***p<0.001, ****p<0.0001. 
A 
B 
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Unpaired t test with Welch's correction  
P value 0.1717 
P value summary ns 
Significantly different (P < 0.05)? No 
One- or two-tailed P value? Two-tailed 
  
Welch-corrected t, df t=1.371 df=253.8 
  
How big is the difference?  
Mean ± SEM of USA (Control) Population 0.1053 ± 0.003619, n=95 
Mean ± SEM of Honduran Population 0.1301 ± 0.01775, n=236 
Difference between means 0.02483 ± 0.01812 
95% confidence interval -0.01085 to 0.06051 
Figure 25. Total IgE sera recognition of rTm-WAP49. Participants from the Trichuris 
trichiura endemic region of Colomoncagua, Honduras (n = 236) and compared to non-
endemic, non-travelled, age-matched controls from the USA (n = 95). Results are plotted on 
a histogram based on the degree of IgE recognition of rTm-WAP49 (0.375 ug/mL) by ELISA. 
(B) Unpaired t test with Welch’s correction comparing the IgE means of the two populations. 
Statistical significance: *p<0.05, **p<0.01 ***p<0.001, ****p<0.0001. 
A 
B 
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Recognition of rTm-WAP49 by T cells in the blood from Trichuris trichiura endemic 
patients 
 To determine whether T cells from Honduran participants recognized rTm-WAP49, we 
measured reactivity of peripheral blood mononuclear cells (PBMCs) to stimulation by flow 
cytometry and Luminex analyses. For flow cytometry, we developed a T cell gating strategy that 
evaluated for the expression of activation and proliferation markers along with production of T 
helper type 1 (TH1) and T helper type 2 (TH2) cytokines (Figure 26). Because of the difficulty in 
collecting PBMC samples in a resource-limited rural setting, we were only able to collect samples 
from 68 of the 236 participants. Assay optimization was focused on a further subset of 
participants with the highest serum IgG specific to rTm-WAP49. 
Two participants (Participant 60 and 90) were initially selected based on their high IgG 
recognition of rTm-WAP49 and determined that their frozen PBMC to have lymphocyte viabilities 
greater than 85% (Table 8A). Aliquots of 250,000 live cells from each participant were stimulated 
with rTm-WAP49 at 50, 20, or 5 ug/mL for 24, 48, 72 or 96 hours (Table 8B). Additionally, Tm-
ES was used as a stimulant for cells from Participant 90 following the same concentrations and 
incubation times as used for stimulation with rTm-WAP49. Antigen-specific stimulation was 
evaluated in terms of CD4+ T cell proliferation (Ki67+) or cytokine production (IL4+, IL-5+, IL-
13+, and IFN-γ). Additionally, we evaluated CD4+CD25+FoxP3+ T regulatory (T reg) cells for 
activation (CD45RA+). We used PMA/I as a positive control reagent for stimulation and observed 
increased production of IL-4, IL-5, IL-13 and IFN-γ by the CD4+ T cells, as well as CD45RA+ T 
regs. However, cells from neither of the two participants showed expression of activation markers 
in response to stimulation with either rTm-WAP49 or Tm-ES. 
Since T cell activation requires both antigen-stimulation as well as co-stimulation, we 
repeated the experiment, with the addition of anti-CD28/49D. In addition to monitoring the 
intracellular cytokine expression, we also evaluated the cytokines produced in the supernatants 
of activated cells by Luminex. Frozen cells from five participants with high anti-rTm-WAP49 IgG 
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levels and cell viabilities above 90% were selected for these assays (Table 9A). We used rTm-
WAP49 (50 ug/mL) and Tm-ES (50 ug/mL) to stimulate 250,000 live cells for 12 h, following the 
protocols from the vendor of the anti-CD28/49D reagents. Additionally, PHA was used as a 
positive control that showed high levels of IL-4, IFN-γ and Ki67 in CD4+ T cells, as well as 
CD45RA expression on T regs (Table 9B). In all these assays,  neither rTm-WAP49 nor Tm-ES 
induced cytokine responses by the CD4+ T cells in any of the participants.  
For four of the five participants we had enough cells to concurrently detect TH2 (IL-4, IL-
5, IL-13) and TH1 (IFN-γ) cytokines in the supernatants after stimulation using the Luminex 
analyses (Table 10). For this, aliquots of 250,000 live cells were co-stimulated with anti-
CD28/CD49D and either media alone, Tm-ES (50 ug/mL), or rTm-WAP49 (50 ug/mL), and 
supernatant samples were collected at 36, 60, 84, 132 hours. We pooled cells from all four 
subjects for stimulation with PHA as a positive control and observed production of significant 
levels of IL-4, IL-5, IL-13, and IFN-γ, relative to media control and also cells stimulated with either 
rTm-WAP49 or Tm-ES. The later data suggests that PBMC from the subjects from the endemic 
area were not responsive to stimulation with rTm-WAP49 or Tm-ES, which may be either due to 
low sensitivity of the assays used or true low frequency of antigen-specific cells as recalled with 
the mouse antigens. 
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Figure 26. T cell gating strategy and representative flow plots. CD4+ T cells were gated 
from live CD3+ lymphocytes. Stimulated CD4+ T cells were further characterized by activation 
(Ki67+), TH2 cytokine production (IL4+. IL5+, and IL-13+), and TH1 cytokine production (IFN-
γ). The CD4+ T regulatory cells were identified by dual staining as CD25+FoxP3+ and 
measured for activation after stimulation as CD45RA+. 
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Participant ID Viability (%) anti-rTm-WAP49 IgG (O.D.) 
60 85.9% 2.3 
90 92.8% 2.2 
Table 8. T helper and T regulatory cell responses to stimulation with rTm-WAP49 
determined by flow cytometry.  (A) Two participants with high IgG recognition of rTm-
WAP49 were selected for PBMC stimulation and optimization and measured for viability. (B) 
250,000 live cells were stimulated with either rTm-WAP49 or Tm-ES at varying concentrations 
(5-50 ug/mL) and time of stimulation (24-96 hours). PMA/I and media alone were used as 
positive and negative controls, respectively. CD4+ T cell response was measured by 
intracellular staining for IL-4, IL-5, IL-13, IFN-γ, and proliferation with Ki67 staining. The 
CD4+CD25+FoxP3+ T regulatory cells were analyzed for activation based on CD45 
expression. 
 
A 
B 
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Participant ID Viability (%) anti-rTm-WAP49 IgG (O.D.) 
41 96.3% 2.0 
60 93.4% 2.3 
68 93.0% 2.4 
102 93.3% 2.3 
120 95.0% 2.3 
Table 9: T helper and T regulatory cell responses to stimulation with rTm-WAP49 and 
Tm-ES after including costimulatory anti-CD28/CD49D for flow cytometry. (A) Five 
participants with high IgG recognition of rTm-WAP49 were selected for PBMC stimulation and 
optimization and measured for viability. (B) 250,00 live cells were stimulated with either rTm-
WAP49 or Tm-ES at 50 ug/mL and co-stimulatory molecules anti-CD28/CD49 for 12 hours. 
PHA and media with co-stimulatory molecules anti-CD28/CD49 were used as positive and 
negative controls, respectively. CD4+ T cell response was measured by intracellular staining 
for IL-4, IL-5, IL-13, IFN-γ, and proliferation with Ki67 staining. The CD4+CD25+FoxP3+ T 
regulatory cells were analyzed for activation based onCD45 expression. Values for all five 
participants were averaged and compared to those of control subjects. 
 
B 
A 
 99 
 
  
Table 10: Cytokine response to stimulation with rTm-WAP49 and Tm-ES after including 
costimulatory anti-CD28/CD49D for Luminex analysis. Cells from four participants with 
the high IgG recognition of rTm-WAP49 were measured for cytokine production in 
supernatant after stimulation. 250,00 live cells were restimulated with either rTm-WAP49 or 
Tm-ES at 50 ug/mL and co-stimulatory molecules anti-CD28/CD49. Samples of supernatant 
were taken at 34, 60, 84, and 132 hours. Supernatants were measured for IL-4, IL-5, IL-13, 
and IFN-γ concentrations by Luminex analysis. Values for all four participants were averaged 
and compared to those of controls. 
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5.4 Discussion 
 To understand the  translatability of the immunogenicity and protective efficacy observed 
for the T. muris derived immunogen rTm-WAP49 in the mouse model for T. trichiura, we 
evaluated the in-vitro antigenic cross-recognition of rTm-WAP49 by serum and PBMC from a 
population endemic for this human whipworm.  
Given that whipworm infection begins early in life, we suspected that a number of 
participants may have had prior exposure, even if they did not have active infection at the time 
of enrollment. Since, there are no T. trichiura-specific antigens to determine prior exposure, we 
chose to evaluate the entire study population for their recognition of rTm-WAP49 in comparison 
to a control age-matched population from the USA with no travel history to a whipworm endemic 
region. Therefore, even though significantly higher IgG recognition of rTm-WAP49 was observed 
in the endemic population, relative to control USA population, it is difficult to judge this as true 
cross-reactivity with T. trichiura. Additional testing with samples from individuals with active T. 
trichiura infection alone would be ideal future direction. 
Pre-existing IgE antibodies to recombinant Na-ASP-2 acquired during natural hookworm 
infection led to an allergic phenotype in select patients, halting vaccine development against Na-
ASP-2 (141). In our studies evaluating for pre-formed IgE recognition of rTm-WAP49 by ELISA, 
we observed significant antigen-specific IgE in five subjects.  However, in general we the mean 
IgE values were not significantly different between participants in the endemic area vs non-
endemic controls. It is important to note that, unlike IgG, levels of IgE antibodies can significantly 
fluctuate in serum when exposed to parasites or allergens, leading to non-specific binding (137). 
One possible future evaluation would be to measure in the serum antigen-specific to total IgE 
ratio, which has been described as a more reliable marker of allergen-specific response (137, 
139). 
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While we observed IgG recognition of rTm-WAP49 from Honduran participants suggest 
a degree of T. trichiura to T. muris cross reactivity, T cells from these individuals did not show 
any activation response after stimulation with rTm-WAP49. Additional attempts investigating 
multiple stimulation techniques that included varying activation times, concentrations of the 
antigen, and methods of evaluation for T cell activation were unsuccessful. Furthermore, we did 
not observe activation with Tm-ES. One explanation is that the frequency of anti-Tm-WAP 
specific T cells in the periphery are too low to respond to the in vitro stimulation protocol adopted. 
Future evaluations could include stimulation of PBMCs with the recombinant T. trichiura WAP 
homolog. In addition, endemic PBMCs could be used to create a humanized SCID mouse model, 
as shown by Taylor and Else (112), and evaluated for immune response to immunization.  
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Chapter VI 
Conclusions and Future Directions 
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6.1 Overall Conclusions 
Human whipworm (Trichuris trichiura) is pervasive intestinal parasite that causes 
malnutrition and inflammatory bowel disease (IBD), predominately among the world’s most 
impoverished billion people. Available treatment strategies have had little impact on the disease 
prevalence or morbidity. A vaccine against human whipworm would provide a low-cost and long-
term solution, yet the identification of candidates is lacking.  
The major goal of this investigation was to identify and assess protective efficacy of 
immunogens corresponding to T. muris, a mouse pathogen with significant gene and protein 
sequence homology to T. trichiura. The central hypothesis that we set out to answer in a murine 
model was that Trichuris spp. stichosome secretory proteins induce protective type 2 immunity.  
 To achieve this goal, we designed a systematic approach of screening T. muris excretory 
secretory (Tm-ES) products for identifying immunogenic proteins and testing their efficacy in the 
susceptible AKR mouse model. This was necessary because, unlike in the cases of hookworm 
or roundworm (1), there were no specific T. trichiura or T. muris candidate immunogens reported, 
and Tm-ES immunized mice exhibit significant protection (>90%) against oral T. muris challenge.   
An immunoscreen of the T. muris adult cDNA expressional library with protective Tm-ES 
antisera identified several targets for determining immunogenicity and efficacy. The most 
abundant candidate was a whey acidic protein (Tm-WAP), followed by the Cysteine-rich 
secretory proteins, Antigen 5, and Pathogenesis-related 1 (CAP-1). BLAST analysis of the T. 
muris genome on WormBase revealed that the Tm-WAP is gene TMUE_s0165000300 and the 
Tm-CAP-1 is TMUE_s0030008500 (120, 121). Both these candidate genes encode proteins 
(WAP and CAP-1) that share a high degree of amino acid sequence identity between T. muris 
and T. trichiura, which suggests that key immunological epitopes may be shared between the 
macromolecules. 
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 The near full-length Tm-WAP (rTm-WAP49) was expressed in P. pastoris X33 with a 
6His-tag at C-terminus for IMAC purification. The most conserved repeat of Tm-WAP, fragment 
8, was expressed in E. coli BL21 with a Necator americanus glutathione s-transferase-1 (Na-
GST-1)-tag at the N-terminus to improve expression and solubility as a recombinant fusion 
protein (rTm-WAP+Na-GST-1). In addition, rNa-GST-1 is a hookworm vaccine candidate (108), 
and was selected among GST-tags for the potential downstream evaluation as a pan-
anthelminthic vaccine candidate. Full-length recombinant Tm-CAP-1 (rTm-CAP-1) protein was 
expressed with an 8 his-tag at C-terminus in Escherichia coli (E. coli) BL21.  
Subcutaneous immunization with rTm-WAP49 or rTm-WAP-F8+Na-GST-1 formulated 
with ISA 720 adjuvant led to a significant reduction in worm burden after oral T. muris challenge 
infection. In contrast, rTm-CAP-1, the second most highly expressed protein recognized by Tm-
ES antisera, was not efficacious.  
Immunization with rTm-WAP49 or rTm-WAP-F8+Na-GST-1 induced a strong TH2 
response (i.e. IL-4, IL-9, and IL-13) at the parasite-draining MLNs, vaccine-draining ILNs, and 
the spleen. While recombinant Tm-CAP-1 did induce some TH2 response, it was significantly 
less effective than either rTm-WAP49 or rTm-WAP-F8+Na-GST-1. During the “critical period” of 
worm expulsion (days 0-21), mice immunized with either rTm-WAP49 or rTm-WAP-F8+Na-GST-
1 showed significant anamnestic immunity in terms of high levels of TH2 cytokines, similar to 
those in mice immunized with Tm-ES. Such responses were not observed in mice immunized 
with rTm-CAP-1. In addition, protection correlated with IgG1 to IgG2a ratio, leading to the highest 
ratios by Tm-ES immunized, followed by rTm-WAP49, then rTm-WAP-F8+Na-GST-1, and finally 
rTm-CAP-1. Antisera from mice immunized with rTm-CAP-1 showed cross-recognition of Tm-ES 
antigen by ELISA, but at nearly a 100-fold less efficiently than the antisera from mice immunized 
with either rTm-WAP49 or rTm-WAP-F8+Na-GST-1 proteins. These results suggest that 
recombinant Tm-WAP is potentially a critical component of Tm-ES for inducing protection against 
T. muris challenge.  
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Since the stichosome plays a critical role in helminth pathogenicity (70, 71), and its 
secretions are considered the primary source of macromolecules in Tm-ES, we used serum from 
mice immunized with rTm-WAP49 and localized the native WAP to the stichosome of T. muris 
within the infected mouse cecum tissues. Immunofluorescence staining suggest WAP is secreted 
from the stichosome into the colonic mucosa, but further detailed exploration is necessary to 
understand how Tm-WAP is produced, trafficked, and ultimately secreted.  
 Both rTm-WAP49 and rTm-WAP-F8+Na-GST-1 proved to be significantly protective and 
were further evaluated for stability, purity, and homogeneity. rTm-WAP-F8+Na-GST-1 was found 
to be stable, with a melting temperature of 57°C by CD, homogenous with one major peak by 
UPLC, and with no signs of contaminants in any of the analytical assays used. We found rTm-
WAP49 to have remarkable thermal stability, with a melting temperature of melting temperature 
of 75°C by CD, and no signs of contaminants. However, various rTm-WAP49 fractions collected 
by HPLC revealed protein oligomerization. Reducing rTm-WAP49 leads to a single 49 kDa 
protein by SDS PAGE, identifying the likely cause of oligomers as disulfide bonding. This is not 
surprising, as whey acidic proteins by definition have a disulfide core domain, and rTm-WAP49 
has 8 of these domains in repeat. Western blot of Tm-ES with rTm-WAP49 antisera revealed 
multiple bands with cross recognition, suggesting that native Tm-WAP exists in a multimeric 
state, similar to that reported for T. trichiura WAP (21). Protein oligomerization has been noted 
as an advantageous feature for protein function and control (163), and thus, may be an inherent 
property of native WAP proteins of Trichuris spp.. Nonetheless, rTm-WAP49 may need to be re-
formulated or re-engineered to create a homogenous protein. 
Lastly, we assessed the translatability of the immunogenicity observed for T. muris-
derived rTm-WAP49 by measuring its cross-reactivity to serum and PBMC samples from 236 
patients from the human whipworm endemic region of Colomoncagua, Honduras. First, we 
selected and confirmed active transmission of T. trichiura by qPCR of parasite DNA extracted 
from stool samples. Sera from patients revealed significant IgG recognition of rTm-WAP49 when 
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compared to sera from non-endemic control individuals. However, given the possibility of cross-
reactivity induced by other nematode infections, a more comprehensive screening will need to 
be performed to validate these findings. Natural infection with T. trichiura does not appear to 
generate pre-formed IgE antibodies as we did not observe their recognition of rTm-WAP49 by 
ELISA . This is a significant finding as pre-formed IgE antibodies to recombinant Na-ASP-2 were 
sufficient to induce generalized urticaria in vaccinated individuals, halting the vaccine’s 
development (141). In addition, after three immunizations in mice with either of the two 
recombinant WAP proteins we did not observe a significant parasite-specific IgE to total IgE ratio 
suggestive of the vaccine inducing the generation of IgE antibodies.  
In summary, we evaluated two Trichuris spp. secretory proteins, Tm-WAP and Tm-CAP-
1 for immunogenicity and protective efficacy against T. muris challenge in the AKR mouse model.  
We found that Tm-WAP, expressed as two independent recombinant proteins, rTm-WAP49 and 
rTm-WAP-F8+Na-GST-1, induced protective type 2 immunity in a murine model manifested in 
terms of high IgG1 to IgG2a ratio and TH2 cytokine production. While both recombinant proteins 
used for immunization and efficacy studies exhibited high degree of purity and stability properties 
assessed by a variety of analytical methods, rTm-WAP49 has a more complex biophysical 
profile, with oligomerization to dimers and trimers through intermolecular disulfide bond 
formation. Recognition of rTm-WAP49 by endemic patient samples suggests that conserved 
epitopes may exist between T. muris and T. trichiura derived WAPs. To our knowledge, this is 
the first study identifying a promising immunogen for further investigation of its vaccine potential 
against T. muris (105) and eventually against T. trichiura.     
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6.2 Future Directions 
The goal of this dissertation was to identify and determine the protective efficacy of 
immunogens from T. muris, the mouse homologue of the human parasite T. trichiura, that would 
aid in the understanding of immune parameters important for the control/treatment of T. trichiura 
infection.  
The research presented here identified two recombinant protein derivatives of T. muris 
whey acidic protein (Tm-WAP) that provided partial protection against worm challenge after 
parenteral immunization in the AKR mouse model. While protective TH2 immune responses were 
detected within the mesenteric lymph nodes of mice after subcutaneous immunization, future 
studies testing mucosal routes of delivery (i.e. oral, sublingual, or intranasal) of the immunogens 
formulated in appropriate mucosal targeting adjuvants could be more effective to induce mucosal 
immunity relevant for this gut pathogen. Since mucosal tissues are more tolerant for induction of 
immune responses, immunogens targeted for mucosal tissues need to be formulated with the 
appropriate adjuvants. The most common adjuvants used are bacterial toxin (wild type or 
mutated) and others include those that effectively modulate innate immune mediators to aid in 
promoting adoptive immune responses. One such adjuvant used in our group has been the 
synthetic glycolipid alpha-galactosylceramide (aGalCer) that activates natural killer T cells (NKT) 
to induce maturation of dendritic cells and promote efficient antigen presentation for enhanced T 
and B cell responses.  
Our data suggests that Tm-WAP is directly secreted from the stichosome into the 
surrounding colonic mucosa, yet it’s function is not known. Since WAP homologues within T. 
trichiura (Tt52 and Tt95) have been recognized for their ability to generate pores in a planar lipid 
bilayer (21–23), it would be important to evaluate whether Tm-WAP exhibits pore-formation 
function and whether Tm-WAP antisera can neutralize this bioactivity.   
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Our research shows that the recombinant near full-length Tm-WAP induces potent TH2 
responses at levels similar to that induced by Tm-ES in key secondary lymphoid tissues, yet, 
Tm-ES elicits near complete protection relative to 40% worm burden reduction by rTm-WAP49. 
To better explore immunization-induced protection, a number of physiological mechanisms that 
are reported to facilitate T. muris expulsion can be explored, such as granulocyte secretion of 
neutralizing proteins and epithelial cell hyperproliferation and turnover (4). Perhaps the most 
important of these physiological mechanisms to evaluate would be intestinal goblet cell secretion 
of mucins and resistin-like molecule-β (RELMβ), largely driven by IL-4, IL-13, and IL-22, which 
block worm motility and epithelial attachment (4).  
An aim of this dissertation was to evaluate human recognition of Tm-WAP. While T. 
trichiura is specific to humans, it may be possible to adapt the helminth to a humanized mouse 
model. Work by Taylor and Else demonstrated that severe combined immunodeficient mice  
infused with endemic human PBMCs could develop an immune response to vaccination with T. 
muris ES and homogenate, suggesting it may be adaptable to a vaccine animal model.  
Through protein characterization, we observed that rTm-WAP49 exists in a multimeric 
state. To determine whether this has any role on immunogenicity or efficacy, rTm-WAP49 could 
be reduced through co-formulation with cysteine amino acids. Proteins reduced in this manner 
have been shown to release their intermolecular (between monomers) disulfide bonding without 
comprising protein stability or functional epitopes (5, 6) 
This thesis represents an important, but early step towards the identification of whipworm 
immunogens that may have utility as future vaccine candidates. While Tm-WAP identified in our 
studies seem to be a promising immunogen capable of inducing strong TH2 immunity, only partial 
protection was achieved in the mouse model employed. Thus, despite the immunodominance of 
Tm-WAP, there may be more antigens that synergistically augment protection through co-
immunization. Therefore, it is important to investigate which of the other macromolecules within 
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the T. muris ES that may be important along with Tm-WAP to induce the sterile immunity seen 
with Tm-ES immunization. 
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